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Despite de advances in surgery and chemotherapy, the outcome of ovarian cancer patients has 
improved very little over the last 40 years. Given that ovarian cancer is an immunogenic tumor, 
immunotherapies offer a great promise as treatment of this dismal disease. We show that follicle-
stimulating hormone (FSH) receptor can be a very specific target that is expressed in >56% of 
human ovarian carcinomas and is a negative prognostic factor. Accordingly, we designed chimeric 
receptors expressing full-length FSH to redirect T-cell cytotoxic activity against these more 
aggressive tumors. In vivo, fully murine FSH-targeted T-cells and low affinity anti-mesothelin 
scFv-targeted Chimeric Antigen Receptor (CAR) T-cells were similarly safe and effective at 
increasing the survival of immunocompetent mice with established and aggressive ovarian 
carcinomas. Notably, both chimeric receptors enhanced the ability of endogenous, pre-existing 
tumor-reactive T-cells to abrogate malignant progression upon adoptive transfer into naïve 
recipients subsequently challenged with the same tumor. Interestingly, chimeric receptor-
expressing CD4 T-cells were superior contributors to these consistent therapeutic benefits, 
compared to their CD8 counterparts. We also found that although chimeric receptor-targeted T-
cells were able to persist as memory lymphocytes without noticeable PD-1-dependent exhaustion 
during end-stage disease, the shedding of FSH receptor from tumor cells diverted the effector 
activity of chimeric receptor-transduced T-cells away from targeted tumor cells. Accordingly, 
although tumor cells remained sensitive to chimeric receptor-driven activities, re-directed 
lymphocytes ultimately disappeared from tumor beds. Thus, although tumor microenvironmental 
factors could limit their effectiveness against established and aggressive epithelial tumors, 
lymphocytes redirected against tumor cells with full-length hormones or low-affinity scFvs induce 
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significant therapeutic benefits by boosting endogenous anti-tumor immunity and show negligible 
toxicity even in the presence of cognate targets in tumor-free tissues.  
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1.1 Adoptive T cell transfer 
Adoptive T cell transfer is a type of adoptive cellular immunotherapy in which T cells are infused 
into patients for their treatment (Tey et al., 2006). The ability of T cells to treat tumors was unveiled 
in the early 1990s. Two almost simultaneous discoveries proved the concept that the transfer of 
antigen specific T cells could eradicate tumors. On the one hand, clinical data showed that the 
transfer of mononuclear cells from haploidentical twins to patients bearing chronic lymphocytic 
leukemia (CLL) was able to produce complete remission (Kolb et al., 1990). On the other hand, 
the transfer of antigen specific T-cells ( against Eppstein Bar Virus (EBV) or Citomegalovirus 
(CMV)) that had been isolated and expanded ex vivo we able to abrogate EBV or CMV associated 
tumors (Rooney et al., 1995, Heslop et al., 1996, Riddell et al., 1992).  
The response of renal carcinoma and posteriorly melanoma with IL-2, a T-cell growth factor, 
fostered the idea that endogenous T-cells were important for tumor rejection (Rosenberg et al., 
1984). The ability of interleukin-2 (IL-2) to allow growth and proliferation of tumor infiltrating 
lymphocytes (TILs) ex vivo from tumor patients led to the generation of T-cells specific for each 
patient’s tumor that could be infused passively into the patient for its treatment (Rosenberg et al., 
1986). This was the beginning of adoptive cell transfer (ACT).  
An advantage of ACT is that the tumor microenvironment can be made more suitable for the 
treatment prior to the T-cell infusion. Tumor microenvironment accommodation has been done 
through nonmyeloablative chemotherapy, consisting in a combination of cyclophosphamide and 
fludarabine, which has a negligible effect on the tumor but facilitates the effect of the adoptively 
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transferred T-cells; and the coinfusion of IL-2 with the TILs (Dudley et al., 2005). The effect of 
ACT was further potentiated with a more aggressive lymphodepletion adding total body irradiation 
(TBI) of 1200 cGy to NMA (Rosenberg et al., 2011).  
Another advantage of ACT is that large numbers of tumor specific T-cells could be generated from 
each patient. However, despite being able to obtain T-cells from multiple tumor types, only 
melanoma patients were able to respond to this therapy, because of the great immunogenicity of 
this this tumor type (Rosenberg et al., 1988). The poor responses in tumor other than melanoma 
led to the development of genetically modified T-cells engineered to express exogenous αβ T-cell 
receptors (TCRs) and chimeric antigen receptors (CAR) that allow the redirection of T-cells 
against specific tumor antigens. 
 
1.2 Chimeric antigen receptors (CARs) 
Redirecting T-cells against tumor antigens using engineered TCRs has the disadvantage that it is 
constrained by human leukocyte antigen (HLA) restriction. Antigen peptides need to bind major 
histocompatibility complex (MCH) molecules in order to go to the surface of the cells and be 
detected by the immune system. Humans express 6 MHC class I alleles (HLA-A, -B and –C from 
each progenitor) and 6 to 8 MHC class II alleles (one HLA-DP, -DQ and one or two –DR from 
each progenitor), each of which has multilple (generally more than 100) alleles. Therefore, the 
engineering of specific TCRs for each allele would suppose a practical problem. To solve this 
problem, T-cells have been engineered to express CARs. CARs consist on an antibody fragment 
(scFv) that binds a particular antigen on the cell surface, fused in frame with T-cell stimulatory 
and co-stimulatory molecules. 
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One of the first studies in which CAR T-cells were applied for solid tumors was renal cell 
carcinoma. The targeted antigen was carbonic anhydrase IX. However, the treated patients showed 
on-target off-tumor effects with liver toxicity that made the treatment not feasible (Lamers et al., 
2006). Similarly, the scFv of Trastuzumab, an antibody raised against ERBB2 was used to generate 
a CAR for treating the wide array of tumors that overexpress this protein.  Again, low expression 
of Her-2 in the lungs generated a fatal pulmonary failure that precluded the use of this target 
(Morgan et al., 2010). The difficulty of finding tumor antigens in the cell surface expressed by 
tumor cells and not healthy cells which would bear intolerable side effects has hampered the 
development of effective CAR therapies for solid tumors.  
Mesothelin has also been targeted due to its overexpression in tumors such as mesothelioma, 
pancreatic carcinoma, ovarian cancer or triple negative breast cancer. To avoid the potential 
adverse effects on the healthy tissues that express mesothelin (mainly peritoneum, pleura and 
pericardium), a CAR expressed by RNA electroporation that only last in the T-cells for about a 
week has been tested (Beatty et al., 2014). However, this required multiple injections of the CAR 
T-cells, which elicited a lethal anaphylactic shock in a patient reacting against the murine scFv of 
the CAR.  
The treatment of hematologic malignancies with CARs has shown impressive responses in 
multiple trials. The target that has been more widely used is CD19, which is expressed by virtually 
all B-cell malignancies (Uckun et al., 1988). Complete responses in patients with acute 
lymphocytic leukemia (ALL) and chronic lymphocytic leukemia (CLL) of 90% and 70% have 
been attained in clinical trials in the University of Pennsylvania and the Pediatric Oncology branch 




1.3 CARs and ovarian cancer 
Epithelial ovarian cancer is one of the most deadly tumors, killing more than 14,000 women each 
year in the US (Jemal et al., 2009). Despite advances in surgical approach and chemotherapy, 5-
year survival rates have barely changed in the last 40 years. Ovarian cancer is, however, an 
immunogenic tumor (Curiel et al., 2004, Zhang et al., 2003, Cubillos-Ruiz et al., 2009, Cubillos-
Ruiz et al., 2010, Huarte et al., 2008, Nesbeth et al., 2009, Scarlett et al., 2009, Scarlett et al., 2012, 
Cubillos-Ruiz et al., 2012), and immunotherapies therefore offer great promise to reverse this 
dismal prognosis (Brayer and Pinilla-Ibarz, 2013, Nelson and Paulos, 2015).  
In recent years, transferring autologous T-cells engineered to express chimeric antigen receptors 
(CARs) has shown impressive cures for patients with chemo-resistant hematologic malignancies 
(Porter et al., 2011, Maus et al., 2014, Kalos et al., 2011). However, several hurdles have so far 
prevented the success of this technology against solid tumors, including ovarian cancer. The most 
challenging is the paucity of specific antigens expressed on the surface of tumor cells that are not 
shared with healthy tissues, to avoid intolerable side effects.  
The follicle-stimulating hormone receptor (FSHR) is selectively expressed in women in the 
ovarian granulosa cells (Simoni et al., 1997) and at low levels in the ovarian endothelium (Vannier 
et al., 1996). Most importantly, this surface antigen is expressed in 50-70% of ovarian carcinomas 
(Zhang et al., 2009, Al-Timimi et al., 1986, Zhang et al., 2013, Minegishi et al., 2000, Nakano et 
al., 1989, Parrott et al., 2001, Wang et al., 2003, Zheng et al., 2000). Given that oophorectomy is 
a standard procedure in the treatment of ovarian cancer, targeting the FSHR should not cause 
damage to healthy tissues. Therefore, FSHR could be an ideal therapeutic target to direct T-cells 
against ovarian cancer using chimeric receptors. 
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Preclinical testing of CARs has been done in immunodeficient xenograft-bearing mice, which do 
not share the targets of chimeric receptors and therefore cannot predict potential adverse effects 
that can happen in a clinical setting. To understand the interaction between CAR T-cells, the host 
immune system and the endogenous target potentially expressed in healthy tissues, we generated 
different fully murine chimeric receptors against mouse targets in immunocompetent mice. While 
CAR T-cells are typically re-directed against tumor antigens through the inclusion of an antibody 
(Ab) fragment (scFv), the FSHR receptor offers the advantage of having a highly specific, natural 
ligand (FSH). Receptor-ligand interactions have been tuned through evolution to maximize 
effectiveness, while Abs are not absolutely specific and Ab fragments often do not preserve the 
binding properties of the original Ig. In addition, FSH is an endogenous molecule, thus avoiding 
the potential immunogenicity of exogenous Ab fragments developed in different species. To 
exploit existing receptor-ligand interactions, we developed new Chimeric Endocrine Receptor 
(CER) constructs that include the two entire subunits of FSH, in frame with a transmembrane 
domain and the intracellular signaling domains successfully used in the treatment of leukemia 
(Porter et al., 2011). To detect potential side effects, we generated a fully murine CER that should 
target any unknown expression of FSHR in healthy tissues in tumor-bearing mice. In addition, we 
generated a fully murine CAR that targets the ovarian cancer antigen mesothelin through a classical 







The PRIMARY OBJECTIVE of this project is to generate a chimeric antigen receptor that is useful 
for the treatment of ovarian cancer. In order to do that we first studied the potential surface proteins 
expressed in ovarian cancer cells. Mesothelin is a well-recognized tumor associated antigen 
overexpressed in ovarian cancer, however, its expression in healthy tissues makes its use in 
immunotherapy controversial. We found that follicle stimulating hormone receptor (FSHR) was a 
very specific antigen, not expressed outside of the ovary, which could be safely used to target 
ovarian cancer through CARs. After generating the CARs to redirect T-cells against FSHR we 
validated the CAR effectiveness in vitro through the ability of CAR T-cells to get activated and 
kill mouse and human tumor cells that expressed the FSHR. Following, we studied the ability of 
this CAR T-cells to treat ovarian cancer in an immunocompetent mouse model.  
The SECONDARY OBJECTIVES were the following: 
- Generate a CAR that should not elicit an anaphylactic response. The use of mouse-derived 
scFv for the generation of the CARs caused death in a patient after multiple infusions due 
to an anaphylactic shock. We had the objective to avoid this by being able to design a CAR 
that is fully human, with no murine counterparts that could elicit such a response.  
- Study if the adoptively transferred T cells are able to boost the endogenous immune 
response. We hypothesize that part of the effect through which CAR T-cells elicit their 
anti-tumor effect is through the boost of the preexisting endogenous immune response, 
through the antigen spreading that would happen after the target cell killing by the CARs. 
We studied this mechanism by using congenic leukocyte markers (CD45.1 and CD45.2) 
that allowed us to differentiate between adoptively transferred T cells and the endogenous 
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T-cells. After treatment, we isolated the endogenous T-cells and tested between the 
different treatment groups for their in vitro and in vivo anti-tumor responses.  
- Study potential failure mechanisms of this therapy. The tumor microenvironment is 
tipically immunosuppressive and may account for the failure of immunotherapies in many 
occasions. In case we are not able to attain tumor rejections we plan to dissect the effects 
of tumor microenvironmental factors on the adoptive T cell transfer therapy. Examples of 
escape to the treatment are immunoediting, overexpression of PD-1 on the surface of the 
T-cells and microenvironment derived suppression through cellular or soluble factors.  
- Study the distribution of the adoptively transferred T cells. In order to more deeply 
understand the therapy with CAR T-cells we will sacrifice tumor bearing mice treated with 
congenic CAR T-cells and study the distribution and phenotype of the adoptively 
transferred T-cells at different time points.  
- Study the potential adverse effects of this therapy on the host. Past research with CARs has 
been done with immunodeficient mice bearing human tumor cell lines and targeting human 
tumor antigens that were not present in the mouse, so some of the adverse effects were not 
predictable. The advantage of using a murine CAR is that we can study, not only the 
interactions of the CAR therapy with the endogenous immune system, but also that the 
targeted molecules will also be present in the host and we will be able to see the adverse 
effects as we would in a clinical setting.   
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3 Materials and methods 
Animals and cell lines  
Wild-type C57BL/6 and Ly5.1 mice were purchased from National Cancer Institute or from 
Charles River. Animal experiments were approved by the Institutional Animal Care and 
Use Committee at The Wistar Institute.  
Parental ID8 cells were provided by Katherine Roby (Department of Anatomy and Cell Biology, 
University of Kansas Medical Center, Kansas City, KS) (Roby et al., 2000) and retrovirally 
transduced to express Defb29 and Vegf-a (Conejo-Garcia et al., 2004).We generated ID8-
Defb29/Vegf-a flank or intraperitoneal tumors as described previously (Cubillos-Ruiz et al., 
2009). Tumors were measured with calipers and tumor volumes calculated as 1/2 × (L x W 
x W), where L is length (longest dimension) and W is width (shortest dimension). To 
generate the ID8-Defb29/Vegf-a-mesothelin cell line, ID8-Defb29/Vegf-a cells were 
transduced 2 times with MIGR1-mesothelin retroviruses and sorted for GFP expression. To 
generate the ID8-Defb29/Vegf-a-FSHR cell line, ID8-Defb29/Vegf-a cells were transduced 
with pBMN-I-GFP-FSHR retroviruses and sorted for GFP expression.  
Double transgenic LSL-K-rasG12D/+p53loxp/loxp (p53/K-ras) mice were generated by obtaining LSL-
K-rastm4Tyj (Jackson et al., 2001) and Trp53tm1Brn (Jonkers et al., 2001) from the NCI mouse models 
of human cancer consortium and bred to a full C57BL/6 background as previously reported 
(Scarlett et al., 2012) . p53/K-ras mice were irradiated two consecutive days with 650 rads followed 
by reconstitution with bone marrow from XBP1f/f or XBP1f/f CD11c-Cre mice. 8 weeks post bone-
marrow reconstitution autochthonous ovarian tumors were initiated by delivery of adenovirus-
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expressing Cre recombinase (ADV-Cre) into the ovarian bursa as previously reported (Flesken-
Nikitin et al., 2003, Dinulescu et al., 2005). 
 
Design of chimeric antigen receptors 
We designed the chimeric antigen receptor constructs using the signal peptide of mouse CD8α, 
followed by either the scFv of the K1 anti-mesothelin antibody or a fusion of the full length FSHβ 
and CGα, peptides linked by a glycine/serine spacer, followed by mouse CD8 hinge and 
transmembrane domain, and an intracellular fragment of mouse 4-1BB and CD3. We ordered the 
construct from Genescript flanked by EcoRI and NotI and cloned into pBMN-I-GFP retroviral 




Human ovarian carcinoma tissues were procured under a protocol approved by the Committee for 
the Protection of Human Subjects at Dartmouth-Hitchcock Medical Center (#17702); and under a 
protocol approved by the Institutional Review Board at Christiana Care Health System (#32214) 
and the Institutional Review Board of The Wistar Institute (#21212263).  
 
Analysis of TCGA data 
Aligned Sequence files related to solid ovarian cancer samples were downloaded from TCGA data 
portal (2015). Downloaded files include whole exon sequencing and outcome data (404 patients). 
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Scores (number of tags in each transcript) were obtained from each sample and normalized with 
respect to total tags in the sample as well as total tags in the chromosome. Tumors with FSHR 
expression values higher than the median FPKM (Fragments Per Kilobase of transcript per Million 
mapped reads) were identified as high expressors. 
 
Retrovirus production  
We generated retrovirus by transfecting Eco-Phoenix cells with pBMN-I-GFP or pBMN-I-GFP-
CAR. Briefly, we plated 4.5e6 Phoenix Ecotropic packaging cells in a 10cm culture dish the 
evening before transfection. The next morning, when cells are at a 80-90% confluence we 
transfected them with a mix of DNA ( 20ug of FSHCER, K1CAR or pBMN), CaCl2 2M (in H2O) 
and 2X HBS buffer (8.0g NaCl, 6.5g HEPES and 10ml of Na2HPO4 solution (5.5g in 500ml)) and 
Chloroquine 100 uM (dissolve 520mg in 10ml H2O). 
Mix DNA (20ug in xuL) with H2O (500-61-x uL) in a 15mL tube. Add 61uL of CaCl2 to mix 
drop by drop. Add 0.5mL of HBS2x to mix drop by drop. Bubble for 15 seconds. Add 2.5uL of 
Chloroquine 25mM to warm DMEM 10% FBS. Remove media from dish very gently (pipeting 
on the side-bottom). Add prewarmed DMEM 10% FBS (now with Chloroquine).Add the 
transfection mix (1mL total) drop by drop. Put dish in incubator. Refresh warm DMEM 10% FBS 
9-11 hours after transfection. On the next morning we changed the media for RPMI 10% FBS 
containing b-mercapto ethanol (3.4ul in 1l) and collected the viral supernatant 24 and 48 hours 
later. Viral supernatants were stored at -80ºC until use.  
 
Transduction of T-cells 
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We isolated naive T-cells from mouse spleens using a negative selection protocol. Briefly, non-T-
cells were removed following red blood cell lysis using magnetic beads (BioMagR Goat anti-Rat 
IgG) to isolate splenocytes bound by the following antibodies: 2.4G2, M170.13, RA3 and M5114.  
Purified T-cells were resuspended in 10cm culture dishes in RPMI 1640 supplemented with 10% 
FBS, Penicillin, Streptomicin, L-Glutamine,  20 U/mL of IL-2 (Peprotech), 1μg/mL of IL-7 
(Peprotech) and 2ug/mL of Concanavalin-A. After 36 hours we resuspended the T-cells at 
106cells/mL in viral supernatant, with IL-2, IL-7 and 8μg/mL of Polybrene and spinfected for 
90min at 32ºC and 1750rpm. Eight hours later, we resuspended the cells in RPMI containing 
10%FBS IL-2 and IL-7 to remove the Polybrene. After 48 hours post-spinfection we sorted T-cells 
for GFP to be used for adoptive cell transfer.  
Alternatively, after red blood cell lysis we resuspended splenocytes at 2x106 cells/mL in a 24-well 
plate with 50U/mL of IL-2 (Peprotech), 1μg/mL of IL-7 (Peprotech) and 50μL/mL of anti-mouse 
CD3/CD28 beads (invitrogen). We performed 2 spinfections at 18 and 36 hours on Retronectin 
coated plates (Takara) and magnetically removed the CD3/CD28 beads at day 4 after isolation. 
We counted the T cell number every 2 days and added RPMI IL-2 IL-7 to keep a concentration of 
106cells/mL. At day 7 T-cells were sorted for GFP and used for adoptive cell transfer.  
 
Preparation of siRNA-PEI nanoparticles and therapeutic in vivo silencing  
 Endotoxin-free rhodamine-labeled and unconjugated polyethylenimine (PEI) for in vivo 
experiments “in vivo-jetPEI” was purchased from PolyPlus Transfection. To generate siRNA-PEI 
nanocomplexes, 50 g of siRNA were complexed with “in vivo-jetPEI” at N/P ratio of 6, following 
the recommendations of the manufacturer and previously optimized conditions (Cubillos-Ruiz et 
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al., 2009).  All siRNA oligonucleotides were from IDT and included 2′-OMe modified nucleotides 
and specific phosphorothioate linkages, as previously reported (Piret et al., 2002).  Sequences for 
the sense and antisense strands are as follows: siLuc sense: 5′-
CuUACgcUGAguaCUUcGAdTsdT-3′, siLuc antisense: 5′-
UCgAAGUACUCAGCgUAAGdTdsT-3′, siXBP1 sense: 5′-cAcccuGAAuucAuuGucudTsdT-3′, 
siXBP1 antisense: 5′-AGAcAAUGAAUUcAGGGUGdTsdT-3′. siIRE1a sense: 5′-
AuGccGAAGuucAGAuGGAdTsdT-3′, siIRE1a antisense: 5’-
UCcAUCUGAACUUCGGcAUdTsdT-3’. 2′-OMe modified nucleotides are in lower case. 
Phosphorothioate linkages are represented by “s” and “d” indicates DNA bases.  
For repeated siRNA treatments, wild-type C57BL/6 female mice were intraperitoneally 
injected with 1x106 aggressive ID8-Defb29/Vegf-A ovarian carcinoma cells, and mice received 
nanocomplexes (50 g of siRNA complexed with “in vivo-jetPEI” at N/P 6, per mouse) at days 8, 
13, 18, 23 and 28 after tumor implantation.  
 
Cytotoxicity assay 
We plated 10000 ID8-Defb29/Vegf-a-Fshr in flat bottom 96 well plate. Before plating the T-cells 
we washed away the tumor conditioned media and added fresh media with no beta mercapto-
ethanol and the appropriate number of T-cells per well (in 200uL). T-cells were FSHCER or mock 
transduced. Following 18 hours we collected T-cells, trypsinized tumor cells and stained them for 





We plated 10000 ID8-Defb29/Vegf-a-Fshr in flat bottom 96 well plate and cocultured overnight 
with FSHCER or mock transduced T-cells. We measured interferon-γ using ELISA (Biolegend) 
and ELISPOT (eBioscience) following manufacturer instructions.  
 
Flow cytometry 
We used a BD LSRII flow cytometer or BD FACSAria cell sorter (BD Biosciences).  
Anti-mouse antibodies used were directly fluorochrome conjugated. We used: anti-CD3e (17A2), 
CD4 (RM4-5), CD8b (YTS156.7.7), CD45 (30-F11), CD45.1 (A20), CD45.2 (104), CD44 (IM7), 
CD69 (H1.2F3), CD62L (MEL-14), PD-1 (29F.1A12) (all from Biolegend or Tonbo Biosciences), 




Frozen human ovarian tumor specimens were mechanically disassociated. Protein extraction, 
denaturation and western blotting were performed as previously described (Rutkowski et al., 




Heart and lungs from mice treated with K1CAR or mock transduced T-cells were collected and 
embedded in OCT (Tissue-Tek) and frozen after which 8µm sections were made from frozen tissue 
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blocks. Slides were then fixed with acetone and washed with PBS. Sections were then blocked 
using α-CD32 followed by staining with biotinylated α-CD45 (30-F11) antibody and completion 
of immunohistochemical procedure according to manufacturer instructions (Vector Labs). Slides 
were viewed using Nikon ECLIPSE 80i microscope and the NIS-Element Imaging software. 
 
Quantitative real-time PCR 
Tissue RNA was isolated from snap-frozen samples by mechanical disruption and extracted using 
RNeasy kits (QIAGEN) according to manufacturer’s instruction. RNA was reverse transcribed 
using High Capacity Reverse Transcription kits (Applied-Biosystems). Relative expression of 
murine CD3e (forward 5’-ACGTACTTGTACCTGAAAGCTC-3’ and reverse 5’-
CCTTCCTATTCTTGCTCCAGT-3’), CD45 (forward 5’-TGAAGAAGAGAGATCCACCCA-3’ 
and reverse 5’-TTTCCAATGTGCTGTGTCCT-3’) and GAPDH (forward 5’-
CCTGCACCACCAACTGCTTA-3’ and reverse 5’-AGTGATGGCATGGACTGTGCT-3’) were 




Unless noted otherwise, all experiments were repeated at least two times and results were 
similar between repeats. Animal experiments used between 3 and 6 mice per group. Differences 
between the means of experimental groups were calculated using a two-tailed unpaired Student’s 
t test. Error bars represent standard error of the mean from independent samples assayed within 
the represented experiments. Survival rates were compared using the Log-Rank test. Tumor 
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growth experiments were compared using slope change through a linear regression analysis. All 






4.1 FSH-targeted chimeric endocrine receptors effectively target human and 
murine ovarian carcinomas 
To understand the relevance of FSHR as an immunotherapeutic target in human ovarian cancer, 
we first analyzed TCGA datasets from 404 high-grade serous ovarian carcinomas. We found that 
56.5% of ovarian cancers express FSHR.  Most importantly, FSHR overexpression is a negative 
prognostic factor in ovarian cancer (Figure 4.1.1), suggesting that FSHR is a good therapeutic 
target for aggressive tumors.  
 
 
Figure 4.1.1 Overexpression of FSHR is a poor prognostic factor in ovarian cancer.  
Survival plot of 404 cases of ovarian cancer from TCGA dataset. We defined FSHR high 
as patients with tumors that had FSHR FKPM above the median, FSHR low as those with 
FKPM below the median and FSHR- as those with no expression measured by FKPM. 
 
Widespread expression of FSHR was confirmed in western-blot analysis of randomly selected 
stage III/IV ovarian carcinomas from our tumor bank (Rutkowski et al., 2015, Stephen et al., 2014), 
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which identified positive expression in ~70% of tumors (Figure 4.1.2), 25% of which exhibit 
similar or higher levels than OVCAR-3 cells, a well-defined positive control (Nakano et al., 1989, 
Choi et al., 2004).  
 
Figure 4.1.2 Approximately 66% of ovarian carcinomas in our tumor bank express FSHR 
Western blot showing expression of FSHR in randomly selected ovarian tumors from 
our tumor bank and OVCAR-3 ovarian cancer cell line. 
 
To target the FSHR by redirecting T-cells, we generated a human chimeric receptor using the full-
length of the two subunits of the human FSH hormone, linked by a glycine/serine spacer, and in 
frame with a transmembrane domain, the intracellular domain of co-stimulatory 4-1BB, and 







Figure 4.1.3 Schematic of FSHCER  
FSHCER is composed by the full length FSHβ and CGα chains of FSH linked by a 
glycine/serine spacer between them and to a CD8α hinge and transmembrane domain, 
which are followed by the intracellular domains of 4-1BB and CD3respectively 
 
Unlike chimeric receptors employing small hormone fragments (Urbanska et al., 2015), FSHCER 
T-cells from HLA-A2+ donors (to minimize allogenicity) killed target OVCAR-3 cells in dose-
dependent, selective and highly effective manner, compared to mock transduced T-cells (Figure 
4.1.4).  
 
Figure 4.1.4 Human FSHCER cytotoxicity against OVCAR-3 
Different numbers of human FSHCER or mock transduced T-cells were coincubated for 
18 hours with 10000 OVCAR-3 cells and cytotoxicity measured by 7-AAD/Annexin V 
staining. 
 
To define the potential of FSHCER T-cells to target established ovarian tumors in 
immunocompetent hosts in the unrestricted presence of targeted FSHR in healthy tissues, as in the 
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clinical setting, we generated a mouse FSHCER with the murine counterparts of all domains 
expressed in human T-cells. As expected, ID8-Defb29/Vegf-a tumor cells, an aggressive ovarian 
cancer model engineered to accelerate peritoneal carcinomatosis and ascites in vivo (Cubillos-Ruiz 
et al., 2012, Cubillos-Ruiz et al., 2009, Scarlett et al., 2009, Stephen et al., 2014), elicited robust 
secretion of IFN- by FSHCER mouse T-cells upon ectopic expression of FSHR, but not in the 
absence of FSHR expression (Figure 4.1.5).  
 
 
Figure 4.1.5 Mouse FSHCER T-cell interferon γ expression upon coculture of ID8-
Defb29/Vegf-a with or without FSHR overexpression 
Mouse T-cells transduced with the FSHCER were cocultured with ID8-Defb29/Vegf-a 
with or without FSHR ectopic expression. After 18 hours supernatants were collected 
and assayed for interferon γ by ELISA. * p<0.05 
 
FSHCER-specific T cell responses were consistent when CD4 and CD8 T-cells were 




Figure 4.1.6 Mouse FSHCER CD4 and CD8 T-cell interferon γ expression  
Mouse T-cells transduced with the FSHCER were first sorted for CD4 or CD8 
expression. Each subset was independently cocultured with ID8-Defb29/Vegf-a with or 
without FSHR ectopic expression. As an additional control, we cocultured ID8-
Defb29/Vegf-a-Fshr with T-cells expressing an irrelevant CAR (K1CAR). After 18 
hours supernatants were collected and assayed for interferon γ by ELISA. * p<0.05 
 
As with their human counterparts, mouse FSHCAR T-cells specifically killed FSHR-expressing 






Figure 4.1.7 Mouse FSHCER cytotoxicity against ID8-Defb29/Vegf-a-Fshr 
Different numbers of mouse FSHCER or mock transduced T-cells were coincubated for 
18 hours with 10000 ID8-Defb29/Vegf-a-Fshr cells and cytotoxicity measured by 7-




Figure 4.1.8 Mouse FSHCER cytotoxicity against ID8-Defb29/Vegf-a-Fshr - microscope 
One hundred thousand mouse FSHCER or mock transduced T-cells were coincubated 
for 18 hours with 10000 ID8-Defb29/Vegf-a-Fshr cells and microscopic pictures of the 
corresponding wells were taken under a light microscope. 
 
Taken together, these results indicate that chimeric receptors using entire subunits of the FSH 
hormone can effectively redirect the cytotoxic activity of T-cells against FSHR+ ovarian 




4.2 Chimeric receptor-expressing T-cells boost pre-existing (endogenous) T-cell-
dependent anti-tumor immunity 
Unlike with immunodeficient mice, the use of the immunocompetent mouse model allowed us to 
dissect the interaction of CAR/CER T-cells with an intact immune system. We hypothesized that 
the specific cytotoxic activity of FSHCER T-cells should result in antigen spreading and decreased 
immunosuppressive burden, which could have a significant effect on pre-existing anti-tumor 
immunity. To test this proposition, we treated different cohorts of CD45.2+ mice growing 
established orthotopic FSHR+ ID8-Defb29/Vegf-a tumors with either congenic CD45.1+ FSHCER 
T-cells or vehicle (PBS).  T-cells of host origin (CD45.2+, to differentiate them from FSHCER T-
cells) were sorted from the peritoneal cavity 1-2 weeks after treatment and subjected to IFN- 
ELISPOT analysis. As shown in Figure 4.2.1, the frequency of endogenous IFN--producing T-
cells responding to dendritic cells pulsed with double (UV + γ)-irradiated ID8-Defb29/Vegf-a 
tumor cells was dramatically higher in mice treated with FSHCER T-cells.  
 
Figure 4.2.1 Endogenous T-cell ELISPOT against tumor antigen (FSHCER treated) 
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Representative interferon gamma ELISPOT of endogenous CD45.2 T-cells derived from 
ascites of FSHCER or PBS treated mice, primed with ID8-Defb29/Vegf-a-Fshr pulsed DCs 
(n=4 per group; 2 independent experiments). * p<0.05 
 
Most importantly, this superior endogenous T-cell response was relevant to delay malignant 
progression, because adoptive transfer of host-derived (CD45.2+) splenic T-cell after treatment 
with FSHCER T-cells (CD45.1+) into naïve syngeneic mice resulted in significantly smaller 
tumors upon re-challenge with the same ID8-Defb29/Vegf-a cells, compared to the effect of T-




Figure 4.2.2 ID8-Defb29/Vegf-a-Fshr flank tumor growth after treatment with endogenous 
T-cells from FSHCER or Mock treated mice. 
Growth kinetics and tumors after resection of ID8-Defb29/Vegf-a-Fshr flank tumors 
treated with endogenous (1e6 CD45.2+GFP- cells administered intraperitoneally) T-cells 
FACS sorted from the spleen of FSHCER or mock-transduced T-cell treated mice (n=4-




To determine whether this boost in endogenous anti-tumor immunity is a general effect of T-cells 
re-directed against tumors by chimeric receptors, we generated an alternative, fully murine CAR. 
We focused on mesothelin, a glycophosphatidylinositol-anchored protein overexpressed in 66-
93% non-mucinous ovarian carcinomas (Ordonez, 2003, Chang et al., 1992).  
We found that the K1 antibody, an Ab that recognizes human mesothelin with low affinity (Chang 




Figure 4.2.3 Mouse mesothelin staining of ID8-Defb29/Vegf-a-Msln with K1 antibody 
Flow cytometry of ID8-Defb29/Vegf-a-Msln using anti-K1 antibody or an isotype control. 
 
Further supporting specific targeting, K1 Abs recognized plate-bound mouse mesothelin but not 




Figure 4.2.4 Mouse mesothelin ELISA with K1 antibody 
Detection of plate bound mouse mesothelin with anti-K1 antibody compared to the levels 
bovine serum albumin by ELISA. * p<0.05 
 
We therefore generated new mouse CAR T-cells using the K1 scFv as a targeting motif (Figure 
4.2.5), and used transduced CD45.1+ T-cells to treat mesothelin-expressing ID8-Defb29/Vegf-a 




Figure 4.2.5 Schematic of K1CAR 
K1CAR is composed by the heavy and light variable fragments (scFv) of the K1 antibody 
linked by a glycine/serine spacer between them and to a CD8α hinge and transmembrane 




As with FSHCER T-cells, administration of K1CAR T-cells induced a significant boost in tumor-
reactive endogenous (CD45.2+) T-cells, as detected through ELISPOT analysis (Figure 4.2.6).  
 
 
Figure 4.2.6 Endogenous T-cell ELISPOT against tumor antigen (K1CAR treated) 
Representative interferon gamma ELISPOT of endogenous CD45.2 T-cells derived from 
ascites of FSHCER or PBS treated mice, primed with ID8-Defb29/Vegf-a-Fshr pulsed DCs 
(n=4 per group; 2 independent experiments). * p<0.05 
 
Similarly, the adoptive transfer of host-derived T-cells stimulated in vivo by the administration of 
CAR T-cells was sufficient to delay malignant progression ( 





Figure 4.2.7 ID8-Defb29/Vegf-a-Msln flank tumor growth after treatment with 
endogenous T-cells from K1CAR or Mock treated mice. 
Growth kinetics and tumors after resection of ID8-Defb29/Vegf-a-Msln flank tumors 
treated with endogenous (1e6 CD45.2+GFP- cells administered intraperitoneally) T-cells 
FACS sorted from the spleen of K1CAR or mock-transduced T-cell treated mice (n=4-
5 per group; 2 independent experiments). * p<0.05 
 
Taken together, these results indicate that the cytotoxic activity of T-cells re-directed against tumor 
cells with chimeric receptors boosts the activity of endogenous anti-tumor T-cells that should be 
able to delay malignant progression regardless of whether tumors lose targeted antigens through 
immunoediting.  
 
4.3 Chimeric receptor-expressing T-cells delay malignant progression in 
immunocompetent ovarian cancer bearing mice  
Given the striking ability of FSHCER T-cells to signal and kill FSHR tumor cells in vitro, and the 
significant boost in pre-existing anti-tumor immunity in vivo, we next determined the therapeutic 
potential of these cells in immunocompetent ID8-Defb29/Vegf-a tumor-bearing mice. Two 
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injections of 1-1.5x106 FSHCER T-cells at days 7 and 14 after tumor challenge were sufficient to 
significantly prolong the survival on this aggressive orthotopic model (Conejo-Garcia et al., 2004, 
Cubillos-Ruiz et al., 2012, Cubillos-Ruiz et al., 2009, Nesbeth et al., 2010, Rutkowski and Conejo-
Garcia, 2015, Scarlett et al., 2009, Stephen et al., 2014), compared to mock-transduced T-cells, in 
multiple independent experiments (Figure 4.3.1). As importantly, no obvious adverse effects were 
observed in these experiments. 
 
 
Figure 4.3.1 Survival plot of ID8-Defb29/Vegf-a-Fshr bearing mice 
Survival plot of mice bearing ID8-Defb29/Vegf-a-Fshr ovarian tumors treated with 
either T-cells bearing the FSHCER or mock-transduced (n=5 per group; 3 independent 
experiments). * p<0.05 
 
Because the expression of FSHR has also been reported in certain metastatic lesions (Siraj et al., 
2013), to demonstrate the general applicability of FSHCER T-cells, we also targeted FSHR-
transduced tumors generated with highly aggressive p53/KRas-driven breast tumor cells 
(Rutkowski and Conejo-Garcia, 2015, Rutkowski et al., 2014) growing in the axillary flank. 
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Supporting broad therapeutic potential, FSHCER T-cells were even more effective at abrogating 
the growth of established tumors at this additional location (Figure 4.3.2).  
 
 
Figure 4.3.2 Tumor growth in A7C11-Fshr bearing mice 
Growth kinetics of A7C11 axillary flank tumors expressing FSHR treated with FSHCER 
or mock transduced T-cells (n=5 per group; 3 independent experiments). * p<0.05 
 
Despite the reproducible therapeutic effects, however, FSHCER T-cells did not induce complete 
rejection of established, aggressive tumors. To compare the effectiveness of hormone vs. scFv 
(antigenic) targeting, we treated established mesothelin-expressing ID8-Defb29/Vegf-a tumor-
bearing mice with K1CAR vs. mock-transduced T-cells. As shown in Figure 4.3.3, expression of 





Figure 4.3.3 Survival plot of ID8-Defb29/Vegf-a-Msln bearing mice 
Survival plot of mice bearing ID8-Defb29/Vegf-a-Msln ovarian tumors treated with 
either T-cells bearing the K1CAR or mock-transduced (n=5 per group; 3 independent 
experiments). 
 
To understand the relative contribution of different T-cell subsets to the reproducible anti-tumor 
effectiveness of FSHCER lymphocytes, we next treated different cohorts of established ID8-
Defb29/Vegf-a tumor-bearing mice with either FSHCER-transduced CD4 or CD8 T-cells, alone 
or in combination. Interestingly, CD4 T-cells expressing chimeric receptors were as effective as a 
mix of unsegregated lymphocytes, while CD8 T-cells alone induced reduced therapeutic benefits 




Figure 4.3.4 Survival plot of ID8-Defb29/Vegf-a-Fshr bearing mice (CD4 vs CD8) 
Survival plot of mice bearing ID8-Defb29/Vegf-a-Fshr ovarian tumors treated with 
either CD4, CD8 or a mixed population of T-cells bearing the FSHCER (n=3-5 per 
group). * p<0.05 
 
Together, our results indicate that T-cells redirected through chimeric receptors that take advantage 
of the natural affinity of a hormone for its receptor can be at least as effective as scFv-targeted 
CAR T-cells. Furthermore, CD4 T-cells are major contributors to consistent therapeutic benefits, 
although incapable of inducing complete rejection of established epithelial tumors. 
 
4.4 Chimeric receptor-expressing T-cells persist in the absence of immunoediting 
To understand tumor-induced mechanisms that could limit the effectiveness of chimeric receptor-
expressing T-cells in vivo, we next tested whether tumor cells could lose the targeted surface 
molecules through immunoediting. Notably, fresh FSHCER T-cells reacted equally strongly by 
secreting IFN- in response to FSHR-transduced tumor cells sorted from the peritoneal cavity of 
mice previously treated with FSHCER- or mock-transduced T-cells, or PBS (Figure 4.4.1), 





Figure 4.4.1 Interferon γ levels of FSHCER after coculture with ID8-Defb29/Vegf-a-Fshr 
from FSHCER, mock or PBS treated mice. 
Levels of interferon- elicited by fresh FSHCER- or mock-transduced T-cells after 
incubation of ID8-Defb29/Vegf-a-Fshr cells (1:10 target:effector ratio), FACS-sorted 
from the peritoneal cavity of orthotopic ID8-Defb29/Vegf-a-Fshr bearing mice treated 
with either FSHCER, mock transduced T-cells or PBS. ns: not significant. 
 
To determine whether chimeric receptor-targeted T-cells persist in ovarian cancer-bearing hosts 
shortly after adoptive transfer, we took advantage of the congenic marker CD45.1 and sacrificed 
FSHR-expressing ID8-Defb29/Vegf-a tumor-bearing mice at days 5, 10 and 15 after 
intraperitoneal administration of FSHCER T-cells. Five days after T-cell administration, we saw 
a peak of FSHCER T-cells in the peritoneal cavity, with similar proportions of CD8 vs. CD4 




Figure 4.4.2 Persistance of transferred T-cells in treated mice 
Five, ten and fifteen days after adoptive T-cell transfer we harvested the peritoneal wash, 
spleen, draining lymph node and bone marrow from ID8-Defb29/Vegf-a-Fshr treated 




Figure 4.4.3 Proportion of CD4 and CD8 in the proportion of T cells transferred 
CD4 T cells preferentially migrated to the spleen compared to CD8. In the peritoneal 
wash, at day 5 the proportion of CD4 and CD8 was similar, but in further timepoints, the 





Both subsets were activated (CD44+CD69+) at tumor (peritoneal) beds at this early stage (45.5% 
and 3.1%, respectively) (Figure 4.4.4).  
 
 
Figure 4.4.4 Percentage of activated CD4 and CD8 in the tumor microenvironment 
We performed a peritoneal wash on days 5, 10 and 15 in ID8-Defb29/Vegf-a-Fshr and 
stained transferred T-cells for CD44+CD69+ to show the activated transferred T cells.  
 
However, proportions and absolute numbers (not shown) of transferred T-cells decreased on days 
10 and 15, accompanied by a higher percentage of CD4 T-cells relative to CD8, and retention of 
activation markers (Figure 4.4.2, Figure 4.4.3 and Figure 4.4.4, above). In both spleen and tumor 
draining lymph nodes, we observed a peak of accumulation at day 10, with trafficking as early as 
day 5. These T-cells are mostly CD4+ (90.5%) with a central memory phenotype (CD44+CD62L+) 




Figure 4.4.5 Memory phenotype of transferred T-cells 
We stained transferred T-cells from the spleen of tumor bearing mice treated with FSHCER 
or K1CER and stained with CD44 and CD62L to look for the distribution at each timepoint 
of central memory (CD44-CD62L+), effector memory (CD44+CD62+) and late effector 
(CD44+CD62-) T-cells.  
 
At terminal stages of malignant progression, FSHCER T-cells were still clearly and reproducibly 
detectable in the spleen (0.6% of total T-cells) (Figure 4.4.6). At this stage, however, no FSHCER 





Figure 4.4.6 FSHCER T-cell are still present in the spleen at terminal tumor stage 
We harvested spleens from ID8-Defb29/Vegf-a-Fshr bearing mice at terminal stage 
(with terminal ascites) and looked for GFP+ T-cells. We found a clear population in the 
spleen. We found no T-cells remaining in the tumor microenvironment (ascites) or bone 
marrow. 
 
Of note, it is also unlikely that exhaustion is a major contributor to the eventual collapse of 
chimeric receptor-expressing T-cells because only a minority of T-cells (8% in CD8 and 31% in 




Figure 4.4.7 Transferred T-cells at terminal stage express low levels of PD1 
CAR T-cells from the spleen at terminal stages showed low levels of PD1 expression. 
 
 To determine whether immunosuppressive factors in tumor ascites could induce T-cell 
death, we co-incubated FSHR-expressing ID8-Defb29/Vegf-a tumor cells and targeted FSHCER 
T-cells in the presence of increasing amounts of tumor-derived ascitic fluid. Unexpectedly, filtered 
(cell-free) tumor ascites increased the reactivity (IFN- secretion) of FSHCER T-cells against their 




Figure 4.4.8 ID8-Defb29/Vegf-a ascites promotes interferonγ secretion of FSHCER T-cells 
in a dose dependent fashion 
Levels of interferon gamma elicited after incubation of ID8-Defb29/Vegf-a-Fshr cells 
(1:10 target:effector ratio) with either FSHCER or mock transduced T-cells with the 
indicated percentages of cell-free ascites from ID8-Defb29/Vegf-a-Fshr bearing mice.  
 
This was the result of recognition of FHSR of tumor cell origin in ascites through recent surface 
shedding, because, firstly, identically treated mock-transduced T-cells did not react against FSHR+ 
tumor cells in the presence of ascites (Figure 4.4.8). 
Also, when we cultured T-cells with ascites in the absence of tumor cells, there was only a relevant 
response when FSHCER T-cells were exposed to ascites that had been previoiusly coincubated 
with FSHR expressing cells, not in the case of ascites without tumor coincubation or with media 
previously incubated with tumor cells (Figure 4.4.9). These results indicate that the acute release 





Figure 4.4.9 Ascites from ID8-Defb29/Vegf-a can activate FSHCER to a lower extent 
Levels of interferon γ elicited after incubating FSHCER or mock transduced T-cells with 
ascites from ID8-Defb29/Vegf-a or media previously coincubated or not with ID8-
Defb29/Vegf-a-Fshr. * p<0.05. 
 
 
Together, these results indicate that chimeric receptor-targeted T-cells persist as memory cells in 
treated ovarian cancer-bearing hosts but they eventually disappear from tumor beds. Shedding of 
continuously expressed molecular target into ascites elicits T-cell activity distally from targeted 
tumor cells, likely contributing to the eventual absence of transferred T-cells from ascites, despite 




4.5 Treatment with FSHCAR and K1CAR is safe 
An important concern regarding the use of chimeric receptor-targeted immunotherapies is the 
occurrence of off-tumor on-target effects. Supporting the restricted pattern of expression of FSHR, 
we did not observe obvious toxicity upon transfer of FSHCER T-cells, in terms of weight loss or 
any signs of discomfort.  
Because mesothelin is expressed in the pleura, pericardium and peritoneum (Chang et al., 1992), 
we focused our attention on potential adverse effects upon adoptive transfer of K1CAR T-cells, 
which have the capacity to recognize mouse mesothelin in tumor-free tissues. Again, treated mice 
showed no obvious adverse effects during follow up. Most importantly, we found no differences 
in the infiltration of total (CD45+) leukocytes in the pleura and pericardium of mice treated with 
K1CAR T-cells, compared to control mice identically treated with mock-transduced T-cells, as 




Figure 4.5.1 Leukocyte infiltration does not differ in pericardium and pleura of K1CAR 
vs mock transduced T-cell treated mice 
We harvested the heart and lungs of mice treated with K1CAR or mock transduced T-
cells, embebbed the tissues in OCT blocks, cut in slides and stained for CD45. 
 
 
Further supporting the absence of increased inflammation in mesothelin-expressing healthy 
tissues, q-PCR did not detect any differences in mRNA expression levels of both CD45 and CD3 
between K1CAR treated vs. mice receiving either mock-transduced T-cells or, most importantly, 




Figure 4.5.2 qRT-PCR shows non-different levels of CD3 and CD45 transcripts in heart 
and lungs of K1CAR or mock transduced T-cells. 
We harvested the heart and lungs of mice treated with K1CAR or mock transduced T-
cells, isolated RNA, made cDNA and analyzed through qRT-PCR for the expression of 
CD3 and CD45. 
 
Overall, our results demonstrate that, although with limited effectiveness due to tumor 
microenvironmental factors, T-cells re-directed against ovarian cancer cells with hormone- or 
scFv-targeted chimeric receptors induce measurable therapeutic benefits with negligible toxicity, 




4.6 XBP-1 expression in dendritic cells promotes immunosuppression in the ovarian 
cancer microenvironment 
Material adapted from Cubillos-Ruiz JR, Silberman PC, Rutkowski MR, Chopra S, Perales-Puchalt A, 
Song M, et al. ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell 
Homeostasis. Cell. 2015;161(7):1527-38. with permission from Cell. 
Aberrant accumulation of unfolded proteins in the Endoplasmic Reticulum (ER) triggers “ER 
stress”, a hallmark feature of many diseases including cancer (Hetz and Glimcher, 2009). XBP1, 
a transcription factor that govenrs ER stress response (Fang and Declerck, 2013), has been 
suggested to operate in cancer cells to influence their survival and growth (Koong et al., 2006, 
Romero-Ramirez et al., 2004). However, its role in modulating the immune cells to allow a tumor-
permissive microenvironment has not been explored.  
To define how constitutive activation of XBP1 in tDCs might influence ovarian cancer 
progression, we developed orthotopic p53/K-ras-driven primary ovarian tumors (Scarlett et al., 
2012) in conditional knockout female mice (Lee et al., 2008) that selectively delete exon 2 of 
Xbp1 in CD11c+ DCs. Notably, ovarian cancer-bearing female mice lacking functional XBP1 in 
CD11c+ DCs (XBP1f/f CD11c-Cre) demonstrated reduced tumor growth (Figure 4.6.1 and 




Figure 4.6.1 Orthotopic p53/Kras ovarian tumors 
p53/K-ras-driven ovarian tumors were generated in hosts reconstituted with bone 
marrow from either XBP1f/f (top) or XBP1f/f CD11c-Cre (bottom) donor mice as 
described in the methods and primary tumors were resected 48 days after intrabursal 
injection of Cre-expressing adenovirus (ADV-Cre). 
 
 
Figure 4.6.2 Growth kinetics of p53/K-ras ovarian tumors in hosts reconstituted with bone 
marrow from the indicated genotypes. 
P53/K-ras ovarian tumors grew significantly faster in hosts reconstituted with XBP1 




These results indicate that XBP1 expression in CD11c+ DCs is necessary for the accelerated 
progression of ovarian cancer. 
To determine whether abrogating XBP1 function selectively in tDCs had significant 
therapeutic effects, mice bearing aggressive ID8-Defb29/Vegf-a ovarian tumors were 
intraperitoneally treated with saline, non-targeting siRNA or XBP1-specific siRNA-PEI 
nanocomplexes. Treatments were administered on days 8, 13, 18, 23 and 28 after tumor 
implantation, following conditions previously optimized by our group (Cubillos-Ruiz et al., 
2009). Ascites accumulation and overall host survival were monitored over time. Consistent with 
prior observations (Cubillos-Ruiz et al., 2009), treatment with immunostimulatory PEI-based 
nanoparticles carrying non-targeting siRNA prolonged survival in cancer-bearing mice compared 
with untreated controls. Nevertheless, superior therapeutic effects were evident in hosts treated 




Figure 4.6.3 PEI-nanocomplexes carrying XBP1 siRNA increased survival in mice 
bearing ID8-Defb29/Vegf-a ovarian tumors 
Mice bearing ID8-Defb29/Vegf-a ovarian tumors were treated on days 8, 13, 18, 23 and 
28 after tumor implantation with PEI-nanocomplexes associated with siRNA against 
XBP1, luciferase or with vehicle (PBS) and survival analyzed. 
 
Therefore, while immunogenic PEI-based nanocomplexes inherently induce beneficial 
outcomes, concomitant abrogation of aberrant XBP1 function in ovarian cancer-associated DCs 







Here we showed that T-cells expressing different chimeric receptors mediate their therapeutic 
activity in part by boosting endogenous, pre-existing anti-tumor immunity, which is relevant to 
delay malignant progression. In addition, the use of the two subunits of the FSH hormone 
effectively redirects the cytotoxic activity of T-cells against ovarian cancer cells, resulting in 
reproducible therapeutic benefits in different preclinical models, eventually limited by tumor-
induced diversion of effector activities distally from tumor cells.  
Our study demonstrates for the first time that host-derived T-cells influenced by chimeric receptor-
transduced lymphocytes contribute to overall effectiveness. Accordingly, recent studies showed 
that short-lived mesothelin-targeting CAR T-cells can induce epitope-spreading and raise Ab titers 
in patients (Beatty et al., 2014). Our work in immunocompetent preclinical models expand these 
mechanisms by demonstrating that CAR T-cells increase endogenous T-cell activity, which is 
sufficient to delay tumor progression. These effects may be particularly important in tumors 
undergoing loss of targeted antigens through immunoediting or deletion of CAR T-cells, because 
polyclonal responses provide additional immune pressure against malignant progression even after 
transferred lymphocytes become ineffective. Interestingly, we did not observe any loss of 
antigenicity in our systems at end-stage disease, despite the fact that FSH-targeted chimeric 
receptor-expression T-cells remained in the host until tumor-bearing mice succumbed to terminal 
disease. Although CAR T-cells have been shown to be reversibly inactivated in solid tumors in a 
PD-1-dependent manner (Moon et al., 2014), in our ovarian tumors we observed PD-1 expression 
in only a minority of FSHCER T-cells persisting in terminal mice. Rather, we found that shedding 
of targeted molecules from the surface of tumor cells into the ascitic fluid is sufficient to divert the 
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effector activity of chimeric receptor-expressing T-cells away from tumor cells. Our results 
therefore unveil a new mechanism of tumor-induced immune evasion that should be considered 
for, at least, the treatment of ovarian cancer patients. 
Another interesting aspect of our study is that, despite superb cytotoxic activity in vitro even at 
low effector:target ratios, and although FSHCER T-cells elicited reproducibly significant survival 
increases in mice with established aggressive ovarian malignancies, all treated mice eventually 
succumb to the disease. Because ovarian cancer is a very challenging disease with a dismal 
prognosis, for these proof-of-concept experiments we limited treatments to two injections and used 
particularly aggressive (and established) tumors. The anti-tumor effects of other CAR T-cells 
could be augmented by additional injections of the CAR T-cells, or by combination with other 
immunotherapeutic interventions (Wang et al., 2014). It is therefore likely that combinatorial 
interventions and applying immunotherapies soon after surgical resection plus chemotherapy will 
further increase the survival of ovarian cancer patients receiving similar treatments.  Our results 
provide a rationale for these interventions because we did not observe any noticeable toxicity 
during the course of our treatments. This was expected for FSHCER T-cells because the only 
healthy tissue where FSHR has been found to be expressed is the ovary (Simoni et al., 1997), 
where ID8 tumor cells preferentially home (not shown). However, we also found any absence of 
toxic effects, or even inflammation, upon the use of mesothelin-targeted CAR T-cells.  
The requirement of CD4 T cells to attain a more effective delay in tumor progression supports the 
relevance of the boost in the endogenous response in the CAR T cell antitumor activity. Both CD4 
and CD8 CAR T cells can elicit a similar cytotoxic activity, however, CD4 T cells may be able to 
orchestrate an effective endogenous antitumor response. 
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Mesothelin is broadly expressed, including in pericardium and pleura. As mesothelin is being 
currently targeted through CAR T-cell interventions in the clinic (Adusumilli et al., 2014, Moon 
et al., 2014, Beatty et al., 2014), concerns about potential off-tumor effects arise. So far, no fatal 
off-tumor specific responses have been reported, but multifactorial T-cell hypofunction in the 
microenvironment of very advanced tumors has also limited the effectiveness of mesothelin CAR 
T-cells (Moon et al., 2014). If CAR T-cells are eventually optimized to induce tumor rejections 
and they persist in treated patients, it is theoretically possible that toxicity will become an issue. 
This could be diminished with the addition of a suicide gene (Hoyos et al., 2010), but long-term 
protection against recurrences would be eliminated. It is therefore possible that low-affinity scFvs 
(such as the K1 clone used in this study) (Chang and Pastan, 1996)) offer a better compromise 
between effectiveness and low toxicity, by targeting (tumor) cells overexpressing the target while 
sparing healthy cells expressing lower levels. 
Overall, our study demonstrates the effectiveness of targeting chimeric receptors for T-cell 
activation using full-length hormones and unveils mechanisms of activity and eventual suppression 
of these interventions that should help understanding previously unknown effects in ongoing and 






6 Current work/Future directions 
6.1 In vivo testing of human FSHCER 
Our development and study of the murine FSHCER has been a tool for the better understanding 
and optimization of the targeting of human FSHR expressing tumors in the clinical setting with 
human FSHCER.  
We have already shown that human T-cells transduced FSHCER show a potent cytotoxicity 
against OVCAR-3, a FSHR expressing ovarian cancer cell line in vitro. However, human tumors 
are heterogeneous, and that heterogeneity cannot be recapitulated with the use of cancer cell lines. 
To accurately recapitulate the heterogeneity of human ovarian cancer in different patients we are 
engrafting fresh advanced ovarian carcinomas that we receive from the long-term collaboration 
between Wistar and the Helen Graham Cancer in NOD-SCID (NSG) mice. We dissect and engraft 
~1mm3 chunks into the ovarian bursa of NSG (severely immunodeficient) mice. Importantly, we 
are also receiving peripheral blood from the same patients, and we are cryopreserving peripheral 
mononuclear cells from each patient. Tumors that engraft (approximately 10-20%) become 





Figure 6.1.1 Ovarian cancer patient derived xenografts 
Three cases of human ovarian carcinomas that we have engrafted in the ovaries of NSG 
mice.  
 
Although their initial progress is slow, we have found that tumors grow faster when they are 
serially engrafted for a second time. Our goal is to generate xenografts for ≥5 primary tumors from 
different patient. These mice will be used to define the effectiveness of FSHCER T cells against 
human ovarian tumors. For that purpose, we will CD3/CD28-expand and transduce the FHSR-
targeting CAR on T cells from the same patient, thus mimicking its potential clinical application.  
As a complement, thanks to a collaboration with Dr Julia Tchou, MD, from the Hospital of the 
University of Pennsylvania, we are also collecting and engrafting triple negative breast cancer 
tissue into the mammary fat pad of NSG mice (Figure 6.1.2). Unlike with ovarian cancer, the 




Figure 6.1.2 Orthotopic breast cancer patient derived xenograft 
NSG mouse bearing a human triple negative breast cancer (arrow) that was engrafted as 
a single cell suspension of tumor cells in the mammary fat pad. 
 
 
We have previously found mesothelin to be a negative prognostic factor for breast cancer (Li et 
al., 2014). We have analyzed Dr Tchou’s tumor bank for mesothelin expressing tumors and used 
those to generate patient derived xenografts in NSG mice. Once we are able to grow the mesothelin 
positive tumors we will pass them into a higher number of NSG hosts and use an established 
mesothelin targeting CAR (Beatty et al., 2014) to study the efficacy of CAR immunotherapy in 
breast cancer as a step for its clinical application. 
 
6.2 Generation of exhaustion resistant T cells by ablation of FoxP1 
TGFβ is lymphocyte inhibitor secreted by multiple cells and frequently overexpressed in 
aggressive cancers (Wrzesinski et al., 2007, Flavell et al., 2010). TGF- can suppress anti-tumor 
CD8 lymphocyte response (Ahmadzadeh and Rosenberg, 2005). We recently reported Forkhead 
box P1 (FoxP1) as a transcription factor that mediates TGFβ immune suppression. This 
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transcription factor is upregulated in the T-cells present in the tumor microenvironment and 
prevent tumor reactive T-cells from proliferating and eliciting tumor rejection (Stephen et al., 
2014). Ablation of Foxp1 in tumor antigen-primed or chimeric receptor anti-tumor T-cells could 
therefore empower lymphocytes to resist immunosuppressive networks in solid tumors. 
In order to generate Foxp1 deficient T-cells we engineered two CRISPR guides for targeting Foxp1 
in the most constant sequence of the gene (towards the 3’). We used the following sequences:  5’-
GCCCGGGCTGAATTGTCAGA-3’ and 5’-GGCCTTGGCGCTGCAAAGAC-3’. We 
electroporated the T-cells with the guide and the plasmid Cas9-GFP using the Amaxa 
electroporation kit P3 and following instructions for naïve T-cells.  
As initial readout of transfection we performed flow cytometry staining for IL-7 receptor α 
(upregulated in Foxp1 deficient cells) and GFP (which the Cas9-GFP plasmid has a reporter) 
(Figure 6.2.1). 
So far, we haven’t been successful in ablating Foxp1 in human T-cells and we are still optimizing 
the protocol. Once we make it work, we plan to ablate Foxp1 in CAR T cells and study their 





Figure 6.2.1 IL-7 receptor α expression by transfected cells and western blot for Foxp1 
expression 
After T-cell electroporation we incubated the T-cells with IL-2 (20U/ml) and IL-7 
(1ug/ml) for 48 hours and stained for IL-7 receptor α and sorted for IL-7 receptor α and  
GFP + (for the detection of the plasmid transfection) T-cells. Above we see the result of 
FACSorting for the mentioned markers (from left to right: no guide, guide 1, guide 2). 
After sorting we extracted proteins from the T-cells and blotted for Foxp1 to ensure the 
absence of the protein due to the gene ablation with the CRISPR. Below is an example 
of an experiment where we did not attain ablation. 
 
 
6.3 Adoptive T cell therapy optimization by modulation of the microbiome 
As we recently published (Rutkowski et al., 2015), commensal microbiota is of paramount 
importance in distal tumor progression. We found that antibiotic depletion of the microbiota in 
mice delayed tumor progression in a sarcoma model. On the other hand, chemo and 
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immunotherapy effectiveness have been shown to be modulated by the gut microbiota (Viaud et 
al., 2015).  Hence, we were interested in the effect that selective populations of microbiota 
depletion could have in the presence of immunotherapy. To validate the differential tumor 
progression in different tumor types, we treated with FSHCER ovarian cancer ID8-Defb29/Vegf-
a-Fshr and A7C11-FSHR with or without microbiota depletion from an antibody cocktail 
containing ampicillin (0.5 mg/ml), neomycin (0.5 mg/ml) and vancomycin (0.25 mg/ml), that we 
diluted in water. In this preliminary experiment we saw that in the A7C11-FSHR breast tumors, 






Figure 6.3.1 A7C11-Fshr tumor bearing mice treated with FSHCER and antibiotic 
cocktail 
(left) Time at which tumors become palpable after tumor cell injection in the flank. Mice  
that received the antibiotic cocktail (Abx) presented a faster breast tumor growth 
compared to those that did not receive antibiotic treatment (No Abx). Two of the tumors 
in the non-antibiotic treated group had not developed at the time of sacrificing the mice 
for analysis. (right) top: tumors of antibiotic treated mice; lower: tumors of non-
antibiotic treated mice. 
 
In the ovarian ID8-Defb29/Vegf-a-Fshr, on the contrary, there seemed to be a slower tumor 
progression associated with antibiotic treatment. At the time of sacrificing the mice for analysis, 
the antibiotic treated mice had smaller spleens (splenomegaly is correlated with tumor progression 
due to the accumulation of myeloid derived suppressor cells) and less ascites than the non-





Figure 6.3.2 ID8-Defb29/Vegf-a-Fshr bearing mice treated with FSHCER and antibiotic 
cocktail 
Spleen weight (p=0.05) and ascites volume (p=0.3) suggested a lower tumor burden in 
mice treated with antibiotic cocktail (Abx) vs non-antibiotic treated (No Abx). 
 
After obtaining this preliminary data, we are planning to start tumors with or without antibiotic 
treatments with and without treatment with FSHCER. Antibiotic treatments will have either all 
three antibiotics or each single antibiotic. After detecting if the effect of antibiotic treatment is 
direct on tumor progression, in the immunotherapy or both, we will sequence the gut microbiota 
in the different groups to study if the depletion of a selective bacterial population is responsible of 





Treatment of ovarian cancer using immunotherapies offers great promise. For being able to 
develop an immunotherapeutic tool for the treatment of ovarian cancer we focused on FSHR, a 
specific molecule that we found to be expressed in 56% of epithelial ovarian carcinomas, and the 
expression of which is associated with a poor prognosis. Given that the target is a receptor, we 
were able to use its natural ligand (FSH) to redirect the T-cells against it generating a CAR that 
will be constituted by protein fragments all from the same species, avoiding the chance of an 
anaphylactic shock.  
Once generated, we were able to test and confirm its activation and cytotoxic activity in vitro 
which was specific towards cells that expressed the FSHR. Accordingly, it was able to delay tumor 
progression both in an ovarian tumor model and a breast tumor model, which we tested due to the 
high expression of this receptor in metastasis and vascularization of other tumors.  
We then tried to get a deeper understanding of the mechanisms by which CAR therapy elicited its 
antitumor response. We found that CAR T-cells were able to boost the preexisting endogenous 
immune system to respond against the tumor. Accordingly, in survival experiments we saw that 
the adoptive transfer of CD4 T-cells was as effective as transferring a mix of CD4 and CD8 T-
cells, whereas the transfer of CD8 T-cells elicited a less pronounced antitumor activity. 
The transferred T-cells migrated from the tumor microenvironment to the different lymphoid 
organs, especially CD4 T-cells and were able to obtain a central memory phenotype. However, in 
advanced stages of tumor progression, transferred T-cells only remained in the spleen and could 
no longer be found in the tumor microenvironment.   
71 
 
The tumor microenvironment of ovarian cancer is very immunosuppressive. Therefore, we 
hypothesized that transferred T-cells were not able to be effectively activated in this 
microenvironment and unable to kill the tumor cells. When we cocultured the T-cells and FSHR-
expressing tumor cells in the presence of cell-free ascites we found a higher activation of the CAR 
T cells compared to the incubation in media. However, this activation also happened in the 
presence of cell-free ascites that had been previously incubated with FSHR-expressing tumor cells. 
Therefore, we hypothesized that proteases in the ascites are causing shedding of the FSHR 
ectodomain, which is activating the T-cells away from the target tumor cells. This is a novel 
immunoevasion mechanism that may be relevant at least in T-cell therapies used in the treatment 
of ascitic tumors. 
Finally, the fact that we could use CARs against mouse targets allowed us to study the potential 
adverse effects that the CAR therapy could have in the clinical setting. We found no clinical 
evidence of distress in the FSHCAR treated mice, however, we did not expect adverse effects due 
to the specificity of the distribution of FSHR. We tested a low affinity CAR targeting mesothelin, 
and analyzed the lymphocytic infiltration of the CAR versus the transfer of non-specific T-cells 
showing no difference and proving that low affinity CARs against targets which are present in 




8 Resumen en lengua oficial de la Universidad de Valencia 
8.1 Introducción 
El cáncer epitelial de ovario es uno de los tumores más letales, matando a más de 14.000 mujeres 
cada año en los EE.UU. A pesar de los avances en cirugía y quimioterapia, las tasas de 
supervivencia a 5 años apenas han cambiado en los últimos 40 años. El cáncer de ovario es, sin 
embargo, un tumor inmunogénico (Curiel et al., 2004, Zhang et al., 2003, Cubillos-Ruiz et al., 
2009, Cubillos-Ruiz et al., 2010, Huarte et al., 2008, Nesbeth et al., 2009, Scarlett et al., 2009, 
Scarlett et al., 2012, Cubillos-Ruiz et al., 2012), y las inmunoterapias suponen una gran esperanza 
para la reversión de este mal pronóstico (Brayer y Pinilla-Ibarz, 2013, Nelson y Paulos, 2015). 
En los últimos años, la transferencia de células T autólogas que expresan receptores de antígenos 
quiméricos (CAR) han producido una gran proporción de remisiones completas en pacientes con 
neoplasias hematológicas quimio-resistentes (Porter et al., 2011, Maus et al., 2014, Kalos et al., 
2011). Sin embargo, varios obstáculos han impedido hasta ahora el éxito de esta tecnología frente 
a tumores sólidos, incluyendo el cáncer de ovario. El mayor desafío es la escasez de antígenos 
específicos expresados en la superficie de las células tumorales que no se comparten con los tejidos 
sanos, para evitar efectos secundarios intolerables. 
El receptor de la hormona folículo estimulante (FSHR) se expresa selectivamente en las mujeres 
en las células granulosas de ovario (Simoni et al., 1997) y en niveles bajos en el endotelio ovárico 
(Vannier et al., 1996). Además, este antígeno de superficie se expresa en el 50-70% de los 
carcinomas de ovario (Zhang et al., 2009, Al-Timimi et al., 1986, Zhang et al., 2013, Minegishi et 
al., 2000, Nakano et al ., 1989, Parrott et al., 2001, Wang et al., 2003, Zheng et al., 2000). Dado 
que la ooforectomía es un procedimiento estándar en el tratamiento de cáncer de ovario, redirigir 
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el sistema inmune contra el FSHR no debería dañar los tejidos sanos. Por lo tanto, FSHR podría 
ser una diana terapéutica ideal para dirigir las células T contra el cáncer de ovario usando CAR. 
Los estudios preclínicos con CAR se han realizado en ratones inmunodeprimidos portadores de 
injertos de tumores humanos, por tanto no presentan las dianas de los CAR en sus tejidos sanos y 
no pueden predecir los efectos adversos. Para comprender la interacción entre el CAR, el sistema 
inmune del huésped y la presencia de la diana del CAR potencialmente expresada en tejidos sanos, 
generamos CAR totalmente murinos contra dianas presentes en el ratón y los utilizamos en ratones 
inmunocompetentes. Mientras los CAR se han dirigido típicamente contra antígenos tumorales a 
través de la inclusión de un fragmento de anticuerpo (scFv), FSHR ofrece la ventaja de tener un 
ligando natural altamente específico (FSH). Además, la FSH es una molécula endógena, evitando 
así la inmunogenicidad potencial de los fragmentos de anticuerpo exógenos desarrollados en 
diferentes especies. Para explotar las interacciones receptor-ligando existentes, hemos 
desarrollado nuevo receptor quimérico endocrino (CER)  que incluyen las dos subunidades enteras 
de FSH, en marco con un dominio transmembrana y los dominios de señalización intracelular 
utilizados con éxito en el tratamiento de la leucemia. Para detectar posibles efectos secundarios, 
generamos un CER totalmente murino que debería atacar cualquier expresión desconocida de 
FSHR en los tejidos sanos de los ratones portadores de tumores. Además, hemos generado un CAR 




El objetivo principal de este proyecto es generar un receptor de antígeno quimérico que pueda 
utilizarse para el tratamiento del cáncer de ovario. Con este fin, estudiamos primero las proteínas 
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de superficie expresadas en las células de cáncer de ovario. La mesotelina es un antígeno cuya 
sobreexpresión en cáncer de ovario es bien conocida, sin embargo, su expresión en los tejidos 
sanos hace que su uso en la inmunoterapia controvertido. Hemos visto que el receptor de la 
hormona folículo estimulante (FSHR) es un antígeno muy específico, al no expresarse fuera del 
ovario, y podría utilizarse de forma segura para tratar el cáncer de ovario utilizando CARs. Tras 
generar los CAR para redirigir las células T contra FSHR, validamos la eficacia del CAR in vitro 
a través de la capacidad de células T con CAR para activarse y matar células tumorales humanas 
y murinas que expresen la FSHR. Después, se estudió la capacidad de este CAR para tratar el 
cáncer de ovario en un modelo de ratón inmunocompetente. 
Los objetivos secundarios fueron los siguientes: 
- Generar un CAR que no produzca una respuesta anafiláctica. El uso de scFv derivado de ratón 
para la generación de los CAR causó la muerte en un paciente después de múltiples infusiones 
debido a un shock anafiláctico. Uno de nuestros objetivos es evitar esto por mediante el diseño de 
un CAR plenamente humano, sin fragmentos murinos que pudieran provocar una respuesta 
anafiláctica. 
- Estudiar si las células T transferidas son capaces de estimular la respuesta del sistema inmune 
endógeno. Nuestra hipótesis es que parte del efecto a través del cual los CAR provocan su efecto 
antitumoral es a través de la potenciación de la respuesta inmune endógena preexistente, a través 
de la difusión de antígenos que ocurre después de la destrucción de células diana por el CAR. 
Estudiamos este mecanismo mediante el uso de marcadores leucocitarios congénicos (CD45.1 y 
CD45.2) que nos permiten diferenciar entre células T adoptivamente transferidas y las células T 
endógenas. Después del tratamiento, aislamos las células T endógenas y estudiamos su respuesta 
antitumoral in vivo e in vitro. 
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- Estudiar posibles mecanismos de fracaso de la inmunoterapia mediante CAR. El microambiente 
tumoral es típicamente inmunosupresor y puede explicar el fracaso de inmunoterapias en muchas 
ocasiones. En caso de que no seamos capaces de conseguir rechazar el tumor tenemos la intención 
de disecar los efectos de los factores del microambiente tumoral en la terapia adoptiva de 
transferencia de células T. Ejemplos de escape al tratamiento pueden ser la inmunoedición, la 
sobreexpresión de PD-1 en la superficie de las células T y la supresión por parte del microambiente 
tumoral debida a factores celulares o solubles. 
- Estudio de la distribución de las células T transferidas adoptivamente. Para comprender más 
profundamente el tratamiento con CAR vamos a sacrificar los ratones con tumor tratados con CAR 
y estudiar la distribución y el fenotipo de las células T transferidas a diferentes puntos temporales. 
- Estudiar los posibles efectos adversos de esta terapia en el paciente. Las investigaciones 
anteriores con CAR se han hecho con ratones inmunodeficientes con líneas de células tumorales 
humanas y dirigidos contra antígenos tumorales humanos que no estaban presentes en el ratón, por 
lo que algunos de los efectos adversos que se han visto a posteriori no eran previsibles. La ventaja 
de usar un CAR murino es que podemos estudiar, no sólo las interacciones de la terapia CAR con 
el sistema inmune endógeno, sino también que las moléculas contra las que dirigimos los CAR 
estarán presente en los tejidos habituales y podremos ser capaces de ver los efectos adversos como 
lo haríamos en la clínica. 
 
8.3 Material y métodos 
Animales y líneas celulares 
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Los ratones C57BL/6 y Ly5.1 se adquirieron del National Cancer Institute o de Charles River. Los 
experimentos con animales fueron aprobados por el Comité de Cuidado y Uso de Animales 
Institucional del Wistar Institute. 
Las células ID8 parentales fueron proporcionadas por Katherine Roby (Departamento de Anatomía 
y Biología Celular de la Universidad de Kansas Medical Center, Kansas City, KS) (Roby et al., 
2000) y transducidas con retrovirus para expresar Defb29 y VEGF-A (Conejo-García et al., 2004). 
Generamos tumores en el flanco axilar o intraperitoneales con ID8-Defb29/Vegf-a como 
describimos previamente (Cubillos-Ruiz et al, 2009). Los tumores se midieron con calipers y 
calculamos los volúmenes tumorales como 1/2 × (L x W x W), donde L es la longitud (dimensión 
más larga) y W es la anchura (dimensión más corta). Para generar las células ID8-Defb29/Vegf-a-
Msln, las células ID8-Defb29/Vegf-a fueron transducidas 2 veces con retrovirus MIGR1-
mesotelina y seleccionadas mediante la expresión de proteína verde fluorescente (GFP). Para 
generar las ID8-Defb29/Vegf-a-Fshr, las ID8-Defb29/Vegf-a fueron transducidas con un retrovirus 
que contenía pBMN-I-GFP-FSHR y seleccionadas mediante la expresión de GFP. 
Diseño de los receptores de antígeno quimérico 
Diseñamos los constructos del receptor de antígeno quimérico usando el péptido señal de CD8α 
murino, seguido de la scFv del anticuerpo anti-mesotelina K1 o una fusión de las subunidades 
FSHβ y CGα, unidos por un espaciador glicina/serina, seguidos del dominio bisagra y 
transmembrana de CD8, y el fragmento intracelular de 4-1BB y CD3z murinos. Pedimos la 
construcción de Genescript, flanqueado por EcoRI y NotI, y la clonamos en el vector pBMN-I-
GFP retroviral. Pedimos las correspondientes secuencias humanas para generar el receptor 





Las muestras de carcinoma de ovario humano fueron adquiridos bajo un protocolo aprobado por 
los comités de ética de la Universidad de Darmouth y The Wistar Institute. 
Análisis de los datos del  TCGA 
Descargamos las secuencias procedientes de muestras de cáncer de ovario del portal de datos 
TCGA (2015). Los archivos descargados incluyen datos de secuenciación de exones y de 
resultados integrales de 404 pacientes. Los tumores con valores de expresión de FSHR superiores 
a la mediana fueron identificados como de expresión alta. 
Producción Retrovirus 
Generamos retrovirus mediante la transfección de células Eco-Phoenix con pBMN-I-GFP o 
PBMN-I-GFP-CAR.  
Transducción de las células T 
Se aislaron las células T de bazos de ratones utilizando un protocolo de selección negativa. Tras 
lisis de glóbulos rojos usamos partículas magnéticas asociadas a anti-IgG de rata junto con los 
siguientes anticuerpos: 2.4G2, M170.13, RA3 y M5114 que se unen a todos los esplenocitos 
excepto a las células T y nos permiten aislarlas. Las células T purificadas se resuspendieron en 
placas de cultivo en RPMI 1640 suplementado con 10% FBS, penicilina, estreptomicina, L-
glutamina, 20 U/ml de IL-2 (Peprotech), 1μg/ml de IL-7 (Peprotech) y 2 μg/ml de Concanavalina-
A. Después de 36 horas se resuspenden las células T en un millón de células/ml en el sobrenadante 
viral, con IL-2, IL-7 y 8μg/ml de Polybrene y se centrifugan durante 90 min a 32ºC y 1750rpm. 
Ocho horas más tarde, se resuspenden las células en RPMI que contiene 10% de FBS IL-2 e IL-7 
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para eliminar el Polybrene. Después de 48 horas post-centrifugación separamos las células T 
infectadas por citometría de flujo para realizar los ensayos. 
Alternativamente, después de la lisis de glóbulos rojos se resuspenden los esplenocitos a 2 millones 
de células/ml en una placa de 24 pocillos con 50 U/ml de IL-2 (Peprotech), 1μg/ml de IL-7 
(Peprotech) y 50μl/ml de anti- ratón de partículas asociadas a anti-CD3/anti-CD28 (Invitrogen). 
Se realizan dos centrifugaciones a las 18 y 36 horas en placas recubiertas de RetroNectin (Takara) 
y quitamos magnéticamente las particulas anti-CD3/anti-CD28 en el día 4 después de establecer 
el cultivo. Contamos el número de células T cada 2 días y añadimos RPMI IL-2 IL-7 para mantener 
una concentración de 1 millón de células/ml. En el día 7 las células T se seleccionan por la 
expresión de GFP y se utilizan para los diferentes ensayos. 
Ensayo de citotoxicidad 
Incubamos 10000 ID8-Defb29/Vegf-a-Fshr en una placa de fondo plano de 96 pocillos. Antes de 
añadir las células T, lavamos el medios acondicionado por el tumor y añadimos medio fresco sin 
beta-mercapto etanol y el número apropiado de células T por pocillo (en 200uL). Después de 18 
horas se recogieron las células T y las células tumorales y se tiñeron para Anexina V y Zombie 
Yellow o 7-AAD (Biolegend). 
Determinación de interferón-γ 
Medimos el interferón-γ en el sobrenadante del cocultivo entre células tumorales y linfocitos T 
mediante ELISA (Biolegend) y ELISPOT (eBioscience) siguiendo las instrucciones del fabricante. 




Utilizamos un citómetro de flujo BD LSRII o “cell sorter” BD FACSAria (BD Biosciences). 
Los anticuerpos anti-ratón utilizados estaban directamente fluorocromo-conjugados. Utilizamos: 
anti-CD3e (17A2), CD4 (RM4-5), CD8b (YTS156.7.7), CD45 (30-F11), CD45.1 (A20), CD45.2 
(104), CD44 (IM7), CD69 (H1.2F3), CD62L (MEL-14), PD-1 (29F.1A12) (todos de Biolegend o 
Tonbo Biosciences), mesotelina (K1, desde Santa Cruz Biotech).  
Immunoblot 
Disociamos mecánicamente muestras de tumor de ovario humano congeladas. La extracción de 
proteínas, la desnaturalización y transferencia se realizaron como se ha descrito previamente 
(Rutkowski et al., 2015). Las membranas se incubaron con anti-FSHR (H-190, Santa Cruz 




El corazón y los pulmones de ratones tratados se recogieron y conservaron en OCT (Tissue-Tek) 
y se congelaron. Después se hicieron secciones a partir de bloques de tejido congelado. Los 
portaobjetos se fijaron a continuación con acetona y se lavaron con PBS. Las secciones se 
bloquearon a continuación utilizando α-CD32 seguido por tinción con α-CD45 biotinilado (30-
F11) y la finalizamos el procedimiento de acuerdo con las instrucciones del fabricante (Vector 
Labs).  
PCR cuantitativa en tiempo real 
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Aislamos ARN de tejidos de muestras congeladas mediante destrucción mecánica y realizmos 
transcripción reversa a ADN copia. Medimos la expresión relativa de CD3e murino (cebadores 5'-
ACGTACTTGTACCTGAAAGCTC-3 'y  5'-CCTTCCTATTCTTGCTCCAGT-3'), CD45 
(cebadores 5'-TGAAGAAGAGAGATCCACCCA-3 'y 5'-TTTCCAATGTGCTGTGTCCT-3') y 
GAPDH (cebadores 5 '-CCTGCACCACCAACTGCTTA-3' y 5'-
AGTGATGGCATGGACTGTGCT-3 ') utilizando SYBR Green (Applied Biosystems) en un 
Sistema de PCR ABI 7500 Fast en tiempo real (Applied Biosystems). 
Análisis estadístico 
A menos que se indique lo contrario, todos los experimentos se repitieron al menos dos veces y 
los resultados fueron similares entre las repeticiones. En los experimentos con animales utilizaron 
entre 3 y 6 ratones por grupo. Las diferencias entre las medias de los grupos experimentales se 
calcularon utilizando la prueba t de Student no pareada de dos colas. Las barras de error 
representan el error estándar de la media a partir de muestras independientes ensayadas dentro de 
los experimentos representados. Las tasas de supervivencia se compararon mediante la prueba de 
log-rank. Los experimentos de crecimiento tumoral se compararon mediante el cambio de 
pendiente a través de un análisis de regresión lineal. Todos los análisis estadísticos se realizaron 




Los receptores endocrinos quiméricos redirigen las células T eficazmente frente al carcinoma 




Para entender la relevancia de FSHR como un diana en el tratamiento del cáncer de ovario, primero 
analiza datos de la base de datos del TCGA, que tiene 404 carcinomas de ovario serosos de alto 
grado. Se encontró que el 56,5% de los cánceres de ovario expresan FSHR. Además, la expresión 
elevada de FSHR es un factor pronóstico negativo en cáncer de ovario (Figure 4.1.1 
Overexpression of FSHR is a poor prognostic factor in ovarian cancer.), lo que sugiere que FSHR 
es una buena diana terapéutica para tumores agresivos. Confirmamos la expresión generalizada de 
FSHR con el análisis de Western-blot de tumores de ovario estadio III / IV seleccionados al azar 
de nuestro banco de tumores (Rutkowski et al., 2015, Stephen et al., 2014), que identificó la 
presencia de FSHR en ~ 70% de los tumores (Figure 4.1.2 Approximately 66% of ovarian 
carcinomas in our tumor bank express FSHR), el 25% de las cuales exhiben niveles similares o 
mayores que las células OVCAR-3, un control positivo bien definido (Nakano et al., 1989, Choi 
et al., 2004). 
Para utilizar el FSHR como diana mediante lar redirección de las células T, generamos un receptor 
quimérico humano usando la longitud completa de las dos subunidades de la hormona FSH 
humana, unidas por un espaciador glicina/serina, en marco con un dominio transmembrana y el 
dominio intracelular de 4-1BB, y CD3 (FSHCER; Figure 4.1.3). A diferencia de los receptores 
quiméricos que emplean fragmentos pequeños de hormonas (Urbanska et al., 2015), el FSHCER 
transducido en células T de donantes HLA-A2 + (para minimizar la reacción alogeneica) causó en 
células OVCAR-3 una citotoxicidad dosis-dependiente, selectiva y eficaz, en comparación con 
células T transducidas con un vector control (Figure 4.1.4). 
Para definir el potencial del FSHCER para tratar tumores ováricos establecidos en modelos 
inmunocompetentes en presencia no restringida de FSHR en los tejidos sanos, como sucedería en 
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el ámbito clínico, generamos un FSHCER murino con los homólogos murinos de todos los 
dominios expresadas en células T humanas. Como era de esperar, las células tumorales ID8-
Defb29/Vegf-a, un modelo de cáncer de ovario agresivo diseñado con una acelerada producción 
de carcinomatosis peritoneal y ascitis in vivo (Cubillos-Ruiz et al., 2012, Cubillos-Ruiz et al., 
2009, Scarlett et al., 2009, Stephen et al., 2014), provocó la secreción robusta de IFN- por células 
T  con FSHCER murino tras la expresión ectópica de FSHR, pero no en la ausencia de expresión 
FSHR (Figure 4.1.5). La respuesta específica del FSHCER se mantuvo cuando las células T CD4 
y CD8 se estimularon de forma independiente (Figure 4.1.6). Al igual que con sus homólogos 
humanos, las células T de ratón con FSHCAR mataron específicamente células tumorales que 
expresan FSHR de una manera dosis-dependiente (Figure 4.1.7 y Figure 4.1.8). Tomados en 
conjunto, estos resultados indican que los receptores quiméricos utilizando subunidades enteras de 
la hormona FSH pueden redirigir eficazmente la actividad citotóxica de las células T contra 
carcinomas de ovario que expresan FSHR, que representan a la mayoría de los tumores humanos. 
 
Las células T que expresan receptores quiméricos potencian la inmunidad antitumoral 
endógena pre-existente 
A diferencia de los ratones inmunodeficientes, el uso del modelo de ratón inmunocompetente nos 
permite disecar la interacción de las células T con receptores quiméricos con un sistema 
inmunológico intacto. Tenemos la hipótesis de que la actividad citotóxica específica de las células 
T con FSHCER da lugar a difusión de antígenos lo que permite una disminución de la carga 
inmunosupresora, lo que podría tener un efecto significativo sobre la inmunidad preexistente 
antitumoral. Para probar esta hipótesis, se trataron diferentes cohortes de ratones CD45.2+ con 
tumores ID8-Defb29/Vegf-a-Fshr  con células T congénicos CD45.1+ transducidas con FSHCER 
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o vehículo (PBS). Entre una y dos semanas después del tratamiento extrajimos las células T 
endógenas y las realizamos con ellas un ELISPOT de interferón γ. Como se muestra en la Figure 
4.2.1, la frecuencia de células T endógenas productoras de IFN- que responden a células 
dendríticas pulsadas con doblemente (UV + γ) irradiadas ID8-Defb29/Vegf-a-Fshr  era 
dramáticamente mayor en los ratones tratados con FSHCER. Además, esta respuesta de las células 
T endógenas superior era suficiente para retrasar la progresión tumoral, ya que la transferencia 
adoptiva de células T endógenas del bazo después del tratamiento con FSHCER en ratones 
singénicos resultó en el desarrollo de tumores más pequeños al volver inyectar los mismos con 
ID8-Defb29/Vegf-a-Fshr, en comparación con el efecto de las células T de ratones tratados con el 
tratamiento control (Figure 4.2.2). 
Para determinar si este aumento en la inmunidad antitumoral endógena es un efecto general de las 
células T redirigidos contra los tumores por los receptores quiméricos, generamos otro CAR 
totalmente murino. Nos centramos en la mesotelina, una glicoproteína que está sobreexpresada en 
66-93% carcinomas de ovario no mucinosos (Ordonez, 2003, Chang et al., 1992). 
Vimos que el anticuerpo K1, un anticuerpo que reconoce la mesotelina humana con baja afinidad 
(Chang and Pastan, 1996), también se une a la mesotelina ratón en células ID8-Defb29/Vegf-a 
transducidas con mesotelina (Figure 4.2.3). Además, el anticuerpo K1 reconoce la mesotelina 
ratón, pero no el control (albúmina) mediante ELISA (Figure 4.2.4). Por lo tanto, generamos un 
nuevo CAR murino utilizando el scFv de K1 (Figure 4.2.5), y utilizamos células T transducidas 
para tratar ratones portadores de tumores ID8-Defb29/Vegf-a que expresan mesotelina. Al igual 
que con el FSHCER, la administración de células T con K1CAR indujo un aumento significativo 
en la actividad endógena antitumoral de las células T, detectada a través ELISPOT (Figure 4.2.6). 
Del mismo modo, la transferencia adoptiva de células T derivadas de ratones tratados con K1CAR 
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fue suficiente para retrasar la progresión tumoral (Figure 4.2.7). Tomados en conjunto, estos 
resultados indican que la actividad citotóxica de las células T redirigidas contra las células 
tumorales con receptores quiméricos aumenta la actividad antitumoral de las células T endógenas 
que deberían ser capaces de retrasar la progresión maligna, independientemente de si los tumores 
pierden los antígenos contra los que están dirigidos los receptores quiméricos a través 
inmunoedición. 
 
Las células T que expresan el receptor quimérico retrasan la progresión maligna en ratones 
inmunocompetentes con cáncer de ovario  
Dada la capacidad de ataque de las células T con FSHCER para matar a las células tumorales que 
expresan FSHR in vitro, y la potenciación de la inmunidad endógena antitumoral in vivo, 
decidimos determinar el potencial terapéutico de estas células en ratones inmunocompetentes con  
tumores ID8-Defb29/Vegf-a. Dos inyecciones de 1-1.5x106 células T que expersaban el FSHCER 
en los días 7 y 14 después de la inyección del tumor fueron suficientes para prolongar 
significativamente la supervivencia en este agresivo modelo ortotópico (Conejo-Garcia et al., 
2004, Cubillos-Ruiz et al., 2012, Cubillos-Ruiz et al., 2009, Nesbeth et al., 2010, Rutkowski and 
Conejo-Garcia, 2015, Scarlett et al., 2009, Stephen et al., 2014), en comparación el tratamiento 
con células T control en múltiples experimentos independientes (Figure 4.3.1). No se observaron 
efectos adversos obvios en estos experimentos. 
Debido a que la expresión de FSHR también se ha reportado en ciertas lesiones metastásicas (37), 
para demostrar la aplicabilidad general del FSHCER, también tratamos tumores de mama murinos 
altamente agresivos transducidas-FSHR (Rutkowski et al., 2014) que crecen en el flanco axilar. 
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Apoyando amplio potencial terapéutico, las células T con FSHCER eran aún más eficaces en freanr 
el crecimiento tumoral en esta ubicación adicional (Figure 4.3.2). 
A pesar de los efectos terapéuticos reproducibles el FSHCER no consiguió inducir el rechazo 
completo de estos tumores. Para comparar la eficacia de la hormona contra el scFv, tratamos 
ratones portadores de tumores ID8-Defb29/Vegf-a que expresan mesotelina con células T 
transducidas con K1CAR o células T control. Como se muestra en la Figure 4.3.3, la expresión de 
K1CAR retrasa la progresión maligna en un grado similar al FSHCER. 
Para entender la contribución relativa de los diferentes subtipos de células T a la eficacia 
antitumoral del FSHCER, tratamos diferentes cohortes de ratones con ID8-Defb29/Vegf-a, ya sea 
con FSHCER en CD4 o CD8 solos o en combinación. Curiosamente, las células T CD4 que 
expresan receptores quiméricos eran tan eficaces como una mezcla de linfocitos no segregados, 
mientras que CD8 células T inducidas por sí solo presentaron un menor beneficio terapéutico 
(Figure 4.3.4). Una tendencia similar se observó con las células T K1CAR transducidas. En 
conjunto, nuestros resultados indican que las células T redirigidas a través de receptores 
quiméricos que se aprovechan de la afinidad natural de una hormona por su receptor pueden ser al 
menos tan eficaz como los CAR redirigidos mediante scFv. Además, las células T CD4 son los 
principales contribuyentes a los beneficios terapéuticos, aunque son incapaces de inducir el 
rechazo total de los tumores epiteliales establecidos. 
 
Las células T que expresan receptores quiméricos persisten en ausencia de inmunoedición 
Para entender los mecanismos que podrían limitar la eficacia de las células T que expresan el 
receptor quimérico in vivo, estudiamos si las células tumorales podrían perder las moléculas de 
superficie mediante un mecanismo de inmunoedición. Las células T con FSHCER reaccionaron 
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de manera semejante en cuanto a secreción de IFN- en respuesta a las células tumorales 
transducidas-FSHR aisladas desde la cavidad peritoneal de los ratones tratados previamente con 
células T transducidas con vector control, FSHCER o PBS (Figure 4.4.1), lo que indica la 
persistencia del FSHR en las células tumorales. 
Para determinar si las células T con receptores quiméricos persisten en los ratones tras el 
tratamiento, utilizamos el marcador congénico CD45.1 y sacrificamos los ratones tratados a días 
5, 10 y 15 después de la administración intraperitoneal de las células T FSHCER. Cinco días 
después de la administración de las células T, vimos un pico de células T FSHCER en la cavidad 
peritoneal, con proporciones similares de CD8 frente a los CD4 (Figure 4.4.2 y Figure 4.4.3). 
Ambas poblaciones estaban activadas (CD44 + CD69 +) en el microambiente tumoral (45,5% y 
3,1%, respectivamente, a día 5) (Figure 4.4.4). Sin embargo, proporciones y números absolutos de 
las células T transferidas disminuyeron en los días 10 y 15, acompañados de un incremento de 
células T CD4 en relación a CD8, y retención de los marcadores de activación (Figure 4.4.2-Figure 
4.4.4). En bazo y ganglios linfáticos de drenaje tumoral, observamos un pico de acumulación en 
día 10, aunque ya había células presentes a día 5. Estas células T son en su mayoría CD4 + (90,5%) 
con un fenotipo de memoria central (CD44 + CD62L +) (Figure 4.4.5) y representaban 0,8% de 
las células T totales. En las etapas terminales de progresión tumoral, las células T con FSHCER 
todavía eran detectables en el bazo (0,6% de las células T totales) (Figure 4.4.6). En esta etapa, sin 
embargo, no hay células T con FSHCER en la ascitis tumoral o la médula ósea.  
Tampoco el agotamiento parecce un importante factor que explique el colapso de las células T que 
expresan el receptor quimérico porque sólo una minoría de las células T (un 8% en CD8 y el 31% 
en las células CD4) expresa PD-1 en la superficie celular (Figure 4.4.7). 
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Para determinar si los factores inmunosupresores en ascitis tumoral podría inducir la inhibición de 
las células T, coincubamos  ID8-Defb29/Vegf-a-Fshr y las células T con FSHCER en presencia de 
cantidades crecientes de líquido ascítico derivado del tumor. Inesperadamente, la ascitis acelular 
aumentó la reactividad (secreción de IFN-) de las células T con FSHCER contra su objetivo de 
una manera dosis-dependiente (Figure 4.4.8). Pensamos que esto es el resultado de reconocimiento 
de FHSR procedente de las células tumorales en la ascitis través de la liberación reciente desde la 
superficie de las células tumorales por diversas razones. En primer lugar, las células T transducidas 
con el vector control no reaccionaron contra las células tumorales FSHR + en presencia de ascitis. 
Además, si cultivamos la ascitis con células T en ausencia de células tumorales, la ascitis sólo 
potencia el incremento de la reactividad de las células T con FSHCER si ha sido incubada 
previamente con células tumorales, pero no de manera directa o cuando el medio de cultivo no 
ascítico ha sido preincubado con células tumorales. Esto último que indica que es necesaria la 
liberación aguda de FSHR a partir de células tumorales activadas por líquido ascítico para la 
activación específica del FSHCER (Figure 4.4.9). 
En conjunto, estos resultados indican que las células T con FSHCER persisten como células de 
memoria en los ratones portadores de cáncer de ovario tratados pero finalmente desaparecen del 
microambiente tumoral. La liberación a la ascitis de la diana terapéutica provoca la activación de 
células T distalmente a las células tumorales, probablemente contribuyendo a la ausencia de 
células T transferidas en la ascitis  a largo plazo, a pesar de la aparente falta de agotamiento y la 
persistencia de las células T en los órganos linfoides. 
 
El tratamiento con FSHCAR y K1CAR es seguro 
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Una preocupación importante con respecto al uso de inmunoterapias con CAR es la aparición de 
efectos en las moléculas diana que se encuentran en tejidos sanos. Apoyando el patrón restringido 
de expresión de FSHR, no observamos toxicidad evidente tras la transferencia de células T 
FSHCER, en términos de pérdida de peso o cualquier signo de malestar. 
Debido a la mesotelina se expresa en la pleura, el pericardio y el peritoneo (33), estudiamos los 
posibles efectos adversos sobre la transferencia adoptiva de células T con K1CAR, que tienen la 
capacidad de reconocer la mesotelina de ratón. Una vez más, los ratones tratados no mostraron 
efectos adversos evidentes durante el seguimiento. No encontramos diferencias en la infiltración 
de leucocitos totales (CD45 +)  en la pleura y el pericardio de ratones tratados con células T 
K1CAR, en comparación con los ratones control idénticamente tratados con las células T control 
por inmunohistoquímica (Figure 4.5.1). Además, no detectamos diferencias en los niveles de 
expresión de ARNm de ambos CD45 y CD3 entre K1CAR  o control por q-PCR (Figure 4.5.2). 
En general, nuestros resultados demuestran que, aunque con una eficacia limitada debido a factores 
procedentes del microambiente tumoral, las células T re-dirigidas contra las células de cáncer de 
ovario con hormonas o scFv inducen beneficios terapéuticos medibles con una toxicidad 
insignificante, a pesar de la expresión de antígenos específicos en los tejidos libres de tumor. 
 
8.5 Discusión 
Aquí demostramos que las células T que expresan diferentes receptores quiméricos median su 
actividad terapéutica, en parte, al aumentar la inmunidad antitumoral endógena, que es capaz de 
retrasar la progresión maligna. Además, el uso de las dos subunidades de la hormona FSH redirige 
de manera eficaz la actividad citotóxica de las células T contra las células de cáncer de ovario, 
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resultando en beneficios terapéuticos reproducibles en diferentes modelos preclínicos, aunque con 
un aumento de supervivencia limitado en caso de la ascitis por la activación distal debida a la 
probable secreción de molélulas diana en el microambiente tumoral. 
Nuestro estudio demuestra por primera vez que las células T endógenas potenciadas por los CAR 
contribuyen a la eficacia antitumoral. Estudios recientes mostraron que los CAR pueden inducir 
difusión de antígenos y elevar los títulos de anticuerpos en pacientes (Beatty et al., 2014). Nuestro 
trabajo en modelos preclínicos inmunocompetentes amplia estos mecanismos al demostrar que los 
CAR son capaces de aumentar la actividad de las células T endógenas, que es suficiente para 
retrasar la progresión tumoral. Estos efectos pueden ser importantes en los tumores sometidos a 
pérdida de antígenos específicos a través inmunoedición o supresión de las células T transferidas, 
porque las respuestas policlonales del sistema inmune endógeno proporcionan presión inmune 
adicional contra la progresión maligna. Curiosamente, no observamos pérdida de antigenicidad en 
nuestros tumores en fase terminal, a pesar de que las células T con FSHCER se persistieron hasta 
que los ratones portadores de tumores sucumbieron a la enfermedad terminal. Aunque otros 
autores han mostrado que los CAR pueden ser inactivados de forma reversible en los tumores 
sólidos de una manera PD-1-dependiente (Moon et al., 2014), en nuestros tumores de ovario se 
observó que la expresión de PD-1 sólo ocurría en una minoría de células transferidas. Sin embargo, 
encontramos que la liberación de moléculas específicas de la superficie de las células tumorales 
en el líquido ascítico es suficiente para desviar la actividad efectora de las células T que expresan 
el receptor quimérico lejos de las células tumorales. Por lo tanto, nuestros resultados revelan un 
nuevo mecanismo de evasión inmune inducida por el tumor que debe ser considerado para, al 
menos, el tratamiento de pacientes con cáncer de ovario. 
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Otro aspecto interesante de nuestro estudio es que, a pesar de excelente actividad citotóxica in 
vitro, y aunque las células T con FSHCER provocaron aumentos de supervivencia reproducible de 
forma significativa en los ratones con cáncer de ovario agresivo, todos los ratones tratados 
finalmente sucumben a la enfermedad. Dado que el cáncer de ovario es una enfermedad con muy 
mal pronóstico, para estos experimentos de prueba de concepto limitamos tratamientos a dos 
inyecciones y a tumores particularmente agresivos. Los efectos podrían ser aumentadas mediante 
inyecciones adicionales de células T, o por la combinación con otras intervenciones 
inmunoterapéuticas (Wang et al., 2014). Por tanto, es probable que las intervenciones 
combinatorias e inmunoterapias aplicadas después de la resección quirúrgica aumentará aún más 
la supervivencia de pacientes con cáncer de ovario que reciben tratamientos similares. Nuestros 
resultados proporcionan un fundamento para estas intervenciones porque no observamos ninguna 
toxicidad apreciable en el curso de nuestros tratamientos. Esto se esperaba para el FSHCER porque 
el único tejido sano donde se ha encontrado FSHR es el ovario (Simoni et al., 1997). Sin embargo, 
también encontramos una ausencia de efectos tóxicos e inflamación con el uso de un CAR de baja 
afinidad para la mesotelina. 
El requisito de la presencia de células T CD4 para lograr un retraso más efectivo en la progresión 
tumoral apoya la relevancia de la potenciación en la respuesta endógena en la actividad antitumoral 
de los CAR. Tanto las células T CD4 y CD8 pueden provocar una actividad citotóxica similar, sin 
embargo, las células T CD4 pueden ser además capaces de orquestar una respuesta antitumoral 
endógena eficaz. 
La mesotelina se expresa en pericardio, pleura y peritoneo sanos. Hoy en día, se está utilizando 
como diana terapéutica para el uso de CAR en diferentes tumores (Adusumilli et al., 2014, Luna 
et al., 2014, Beatty et al., 2014) y existe la preocupación por la aparición potencial de efectos 
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adversos en este tejido sano. Hasta el momento, no se han publicado efectos adversos específicos 
letales, pero la hipofunción multifactorial de las células T en el microambiente de tumores muy 
avanzados también ha limitado la eficacia del CAR (Luna et al., 2014). Si se optimiza el 
tratamiento con CAR para inducir el rechazo de tumores y que persistan las células T en los 
pacientes tratados, es posible que la toxicidad se convertirá en un problema. Esta podría disminuir 
con la adición de un gen suicida (Hoyos et al., 2010), pero la protección a largo plazo contra las 
recurrencias se eliminaría. Por tanto, es posible que los scFv de baja afinidad (tales como el clon 
K1 utilizado en este estudio) (Chang y Pastan, 1996)) ofrezcan una mejor relación entre la eficacia 
y baja toxicidad, por dirigirse a las células (tumor) que sobreexpresan la diana terapéutica sin 
afectar a las células sanas que expresan niveles más bajos. 
En general, nuestro estudio demuestra la eficacia de los receptores quiméricos para la activación 
de las células T utilizando hormonas y da a conocer mecanismos de la actividad y supresión de 
estas intervenciones. Estos datos deben ayudar a la comprensión de efectos previamente 
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